NZ733805B2 - Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor - Google Patents
Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor Download PDFInfo
- Publication number
- NZ733805B2 NZ733805B2 NZ733805A NZ73380516A NZ733805B2 NZ 733805 B2 NZ733805 B2 NZ 733805B2 NZ 733805 A NZ733805 A NZ 733805A NZ 73380516 A NZ73380516 A NZ 73380516A NZ 733805 B2 NZ733805 B2 NZ 733805B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- methyl
- thiazolo
- phenyl
- oxo
- Prior art date
Links
- 210000000234 Capsid Anatomy 0.000 title claims abstract description 87
- 239000000556 agonist Substances 0.000 title claims abstract description 72
- 239000003112 inhibitor Substances 0.000 title claims abstract description 61
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 61
- 102100006355 TLR7 Human genes 0.000 claims abstract description 90
- 101700075266 TLR7 Proteins 0.000 claims abstract description 89
- 239000000203 mixture Substances 0.000 claims abstract description 77
- 208000002672 Hepatitis B Diseases 0.000 claims abstract description 20
- -1 5-aminooxo-thiazolo[4,5-d]pyrimidinyl Chemical group 0.000 claims description 216
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 76
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 73
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 46
- 239000011780 sodium chloride Substances 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 40
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 20
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000000069 prophylaxis Effects 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 9
- 208000001756 Virus Disease Diseases 0.000 claims description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- QDGZDCVAUDNJFG-FXQIFTODSA-N Entecavir Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 claims description 4
- 229960001627 Lamivudine Drugs 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 229960000980 entecavir Drugs 0.000 claims description 4
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 3
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N Tenofovir Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 claims description 3
- 229960004556 Tenofovir Drugs 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- IQFYYKKMVGJFEH-CSMHCCOUSA-N Telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims description 2
- 229960005311 telbivudine Drugs 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 claims 3
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 abstract description 9
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 337
- 241000700721 Hepatitis B virus Species 0.000 description 141
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 93
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 71
- 239000000243 solution Substances 0.000 description 46
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 40
- 238000002360 preparation method Methods 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- 229960000583 Acetic Acid Drugs 0.000 description 30
- 235000011054 acetic acid Nutrition 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 26
- 210000002966 Serum Anatomy 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 21
- 239000007787 solid Substances 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- 239000007832 Na2SO4 Substances 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 18
- 235000011152 sodium sulphate Nutrition 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000012043 crude product Substances 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
- 238000010172 mouse model Methods 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 230000003612 virological Effects 0.000 description 12
- 210000004027 cells Anatomy 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 8
- 230000000840 anti-viral Effects 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 230000001684 chronic Effects 0.000 description 8
- 230000000875 corresponding Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atoms Chemical group C* 0.000 description 7
- 201000009910 diseases by infectious agent Diseases 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 102000004965 antibodies Human genes 0.000 description 6
- 108090001123 antibodies Proteins 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 6
- LOWHAEXKCMFUMV-UHFFFAOYSA-N 5-hydroxy-1,3-oxathiolane-2-carboxylic acid Chemical compound OC1CSC(C(O)=O)O1 LOWHAEXKCMFUMV-UHFFFAOYSA-N 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000038129 antigens Human genes 0.000 description 5
- 108091007172 antigens Proteins 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 102000002689 toll-like receptors Human genes 0.000 description 5
- 108020000411 toll-like receptors Proteins 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- OKGNMRKOGWTADH-UHFFFAOYSA-N 1,4-dihydropyrimidine Chemical compound C1C=CNC=N1 OKGNMRKOGWTADH-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 229940068968 Polysorbate 80 Drugs 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001809 detectable Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 3
- SUPKOOSCJHTBAH-UHFFFAOYSA-N 2-(6-aminopurin-9-yl)ethoxymethylphosphonic acid Chemical compound NC1=NC=NC2=C1N=CN2CCOCP(O)(O)=O SUPKOOSCJHTBAH-UHFFFAOYSA-N 0.000 description 3
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N Silver nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 229960001997 adefovir Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
- 230000001086 cytosolic Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N (+)-tartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-(1R,3R,4S)-menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- OBOHMJWDFPBPKD-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 OBOHMJWDFPBPKD-UHFFFAOYSA-N 0.000 description 2
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N 2,2,2-trifluoroethyl alcohol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 2
- PIZVRLVKXWEMGO-UHFFFAOYSA-N 2-chloro-3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1Cl PIZVRLVKXWEMGO-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- OTLNPYWUJOZPPA-UHFFFAOYSA-M 4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-M 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N Benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 102000004040 Capsid Proteins Human genes 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 229920002759 Circular DNA Polymers 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 210000004443 Dendritic Cells Anatomy 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 101700046422 IFNA Proteins 0.000 description 2
- 102000007576 Interferon Regulatory Factor-7 Human genes 0.000 description 2
- 108010032036 Interferon Regulatory Factor-7 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 229960000448 Lactic acid Drugs 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- FTDXEVXMYRJESG-UHFFFAOYSA-N NC1=NC=C2S(=O)C=NC2=N1 Chemical compound NC1=NC=C2S(=O)C=NC2=N1 FTDXEVXMYRJESG-UHFFFAOYSA-N 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N Trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- 210000002845 Virion Anatomy 0.000 description 2
- 230000001594 aberrant Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000005997 bromomethyl group Chemical group 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 108090000464 transcription factors Proteins 0.000 description 2
- 102000003995 transcription factors Human genes 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 239000001677 (2R,5R)-1,4-dithiane-2,5-diol Substances 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KFHQOZXAFUKFNB-UHFFFAOYSA-N 1,3-oxathiolanyl Chemical group [CH]1OCCS1 KFHQOZXAFUKFNB-UHFFFAOYSA-N 0.000 description 1
- YUIOPHXTILULQC-UHFFFAOYSA-N 1,4-Dithiane-2,5-diol Chemical compound OC1CSC(O)CS1 YUIOPHXTILULQC-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VZIHTQKMHLOIII-UHFFFAOYSA-N 3,5-dihydro-2H-furan Chemical group [CH]1CCOC1 VZIHTQKMHLOIII-UHFFFAOYSA-N 0.000 description 1
- HSUCYMJBFHBMTB-UHFFFAOYSA-N 3-fluoro-2-methylbenzaldehyde Chemical compound CC1=C(F)C=CC=C1C=O HSUCYMJBFHBMTB-UHFFFAOYSA-N 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3H-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-Nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- YDWRPBIUDIYAOX-UHFFFAOYSA-N 5-amino-3,4-dihydro-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1NC(N)=NC2=C1SC(=O)N2 YDWRPBIUDIYAOX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N Anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N Diethylethanolamine Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000033180 ERVK-6 Human genes 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710027967 ERVW-1 Proteins 0.000 description 1
- 210000001163 Endosomes Anatomy 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 102100012864 GADD45B Human genes 0.000 description 1
- 101710037036 GADD45B Proteins 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N Glyoxylic acid Natural products OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- YKFRUJSEPGHZFJ-UHFFFAOYSA-N N-trimethylsilylimidazole Chemical compound C[Si](C)(C)N1C=CN=C1 YKFRUJSEPGHZFJ-UHFFFAOYSA-N 0.000 description 1
- KOTGQQFDBAICGK-BWZSGCSDSA-N O1[C@H](C1)C1OC2C(O1)OCC2 Chemical compound O1[C@H](C1)C1OC2C(O1)OCC2 KOTGQQFDBAICGK-BWZSGCSDSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N Resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 Resiquimod Drugs 0.000 description 1
- 101700050102 SLAC Proteins 0.000 description 1
- 101710023234 Segment 5 Proteins 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 102100012088 TLR3 Human genes 0.000 description 1
- 101700023131 TLR3 Proteins 0.000 description 1
- 102100006354 TLR8 Human genes 0.000 description 1
- 101700071772 TLR8 Proteins 0.000 description 1
- 229960004559 Theobromine Drugs 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 108091005908 Type I transmembrane proteins Proteins 0.000 description 1
- 101700028070 VPX Proteins 0.000 description 1
- 241000625014 Vir Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 102000004640 Viral Envelope Proteins Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 102000016350 Viral Proteins Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- KALKCYZKBYICSO-UHFFFAOYSA-N [1,3]thiazolo[4,5-d]pyrimidine 1-oxide Chemical compound C1=NC=C2S(=O)C=NC2=N1 KALKCYZKBYICSO-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 102000035425 adaptor proteins Human genes 0.000 description 1
- 108091005736 adaptor proteins Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000003281 allosteric Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- VWLWTJHKQHRTNC-UHFFFAOYSA-L dipotassium;8-anilino-5-(4-anilino-5-sulfonatonaphthalen-1-yl)naphthalene-1-sulfonate Chemical compound [K+].[K+].C=12C(S(=O)(=O)[O-])=CC=CC2=C(C=2C3=CC=CC(=C3C(NC=3C=CC=CC=3)=CC=2)S([O-])(=O)=O)C=CC=1NC1=CC=CC=C1 VWLWTJHKQHRTNC-UHFFFAOYSA-L 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- HAWROYHPFXYIGS-UHFFFAOYSA-N ethyl 3-amino-2,2-dimethylpropanoate;hydrochloride Chemical compound Cl.CCOC(=O)C(C)(C)CN HAWROYHPFXYIGS-UHFFFAOYSA-N 0.000 description 1
- FAASZJGSPHPJJY-UHFFFAOYSA-N ethyl 4-(2-bromo-4-fluorophenyl)-6-(morpholin-4-ylmethyl)-2-(3H-pyrrol-2-yl)-1,4-dihydropyrimidine-5-carboxylate Chemical compound N1C(C=2CC=CN=2)=NC(C=2C(=CC(F)=CC=2)Br)C(C(=O)OCC)=C1CN1CCOCC1 FAASZJGSPHPJJY-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;N-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- JUHDUIDUEUEQND-UHFFFAOYSA-N methylium Chemical compound [CH3+] JUHDUIDUEUEQND-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 210000000605 viral structures Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Abstract
The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient. itis B patient.
Description
ed Treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
The present invention is generally directed to itions for treating hepatitis B virus
ion. Methods for treating hepatitis B virus infection are described herein. In particular, the
present invention is ed to a combination therapy comprising administration of a TLR7
agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic tis B
patient.
FIELD OF THE INVENTION
Chronic infection of Hepatitis B virus (HBV) is a serious public health problem
worldwide, with more than 240 million people chronically infected worldwide. HBV belongs to
the aviridae family of viruses. Following entry into cyte, its viral genome is
delivered into nucleus where a covalently closed circular DNA (cccDNA) is formed through
DNA repair of partially double-stranded viral genomecccDNA serves as the template for
transcription of viral RNAs. Viral pre-genomic RNA interacts with other two viral components,
capsid n and polymerase to form capsid particles where viral DNA ation occurs.
HBV has an icosahedral core comprising of 240 copies of the capsid (or core) protein. The
inant biological function of capsid protein is to act as a structural protein to encapsidate
pre-genomic RNA and form immature capsid particles in the cytoplasm. This step is prerequisite
for viral DNA replication. When a near full-length relaxed circular DNA is formed through
reverse-transcription of viral pregenomic RNA, an immature capsid becomes a mature .
Most copies of the encapsidated genome efficiently associate with cellular lipids and viral
envelope proteins (S, M, and L) for virion assembly and secretion. However, non-infectious
particles are also produced that greatly outnumber the infectious virions. These empty,
enveloped particles are referred to as al particles (SVPs). The S, M, and L envelope
proteins are sed from a single ORF (open reading frame) that contains three different start
codons. All three proteins share a 226aa sequence, the S-domain, at their C-termini. S-domain
contains the HBsAg epitope (Lambert, C. & R. Prange. Virol J, 2007, 4, 45).
Many observations showed that several HBV viral proteins could counteract the initial host
cellular response by interfering with the viral ition signaling system and subsequently the
interferon (IFN) antiviral activity. Among these, the excessive secretion of HBV empty al
particles may participate to the maintenance of the immunological tolerant state observed in
cally ed patients (CHB). The persistent exposure to HBsAg and other viral antigens
can lead to HBV-specific T-cell on or to progressive functional impairment (Kondo et al.
Journal of Immunology 1993, 150, 671; Kondo et al. Journal of l Virology 2004,
74, 3; ro et al. Gastroenterology, 2010, 138, 682-93;). Moreover HBsAg has been
reported to suppress the function of immune cells such as monocytes, dendritic cells (DCs) and
natural killer (NK) cells by direct interaction (Op den Brouw et al. Immunology, 2009b, 126,
280-9; Woltman et al. PLoS One, 2011, 6, e15324; Shi et al. J Viral Hepat. 2012, 19, e26-33;
Kondo et al. ISRN Gasteroenterology, 2013, Article ID 935295).
HBsAg quantification is a biomarker for prognosis and treatment response in chronic
hepatitis B. HBsAg loss and nversion is the goal for clinical cure, but is rarely observed in
chronically infected patients. t therapy such as Nucleos(t)ide analogues that inhibit HBV
DNA synthesis does not directly affect HBsAg level. Nucleos(t)ide analogs, even with prolonged
therapy, have demonstrated very low rates of HBsAg clearance comparable to those ed
naturally (Janssen et al. Lancet, 2005, 365, 123-9; Marcellin et al. N. Engl. J. Med., 2004, 351,
1206-17; Buster et al. logy, 2007, 46, 388-94).
Toll-like receptors (TLRs) detect a wide range of conserved pathogen-associated molecular
patterns ). They play an important role of sensing invading pathogens and subsequent
initiation of innate immune responses. There are 10 known members of the TLR family in
human, which are type I transmembrane proteins featuring an extracellular leucine-rich domain
and a cytoplasmic tail that contains a conserved Toll/ interleukin (IL)-1 receptor (TIR) domain.
Within this , TLR3, TLR7, TLR8, and TLR9 are located within endosomes. TLR7 can be
activated by binding to a specific small molecule ligand (i.e., TLR7 agonist) or its native ligand
(i.e., single-stranded RNA, ssRNA). Following binding of ssRNA to TLR7, the receptor in its
dimerized form is believed to undergo a structural change leading to the subsequent recruitment
of adapter proteins at its cytoplasmic domain, including the myeloid differentiation primary
response gene 88 ). Following the initiation of the receptor signalling cascade via the
MyD88 pathway, cytoplasmic transcription factors such as interferon regulatory factor 7 (IRF-7)
and nuclear factor kappa B (NF-κB) are activated. These transcription factors then translocate to
the nucleus and initiate the transcription of various genes, e.g., IFN-α and other antiviral
cytokine genes. TLR7 is predominately expressed on plasmacytoid cells, and also on B-cells.
Altered responsiveness of immune cells might contribute to the reduced innate immune
ses during chronic viral infections. Agonist-induced activation of TLR7 might therefore
represent a novel approach for the treatment of chronic viral infections. (D. J Connolly and L. AJ
O’Neill, Current Opinion in Pharmacology 2012, 12:510–518, P. A. Roethle et al, J. Med. Chem.
2013, 56, 7324−7333).
Treatment with an oral TLR7 agonist represents a ing solution to provide greater
efficacy with better tolerability. Pegylated IFN-α (PEG-IFN-α) is currently used to treat chronic
HBV and is an alternative to potentially life-long ent with antiviral nucleos(t)ide
analogues. In a subset of chronic HBV patients, PEG-IFN-α y can induce sustained
immunologic l of the virus following a finite duration of therapy. However, the percentage
of HBV patients that e seroconversion with interferon therapy is low (up to 27% for
HBeAg-positive ts) and the treatment is typically poorly tolerated. rmore, functional
cure (defined as HBsAg loss and seroconversion) is also very infrequent with both PEG-IFN-α
and s(t)ide treatment. Given these limitations, there is an urgent need for improved
therapeutic options to treat and induce a functional cure for chronic HBV. Treatment with an oral,
small-molecule TLR7 agonist is a promising approach that has the ial to provide greater
efficacy and tolerability (T. Asselah et al, Clin Liver Dis 2007, 11, 839–849).
HBV capsid protein plays essential roles in HBV replication.
Heteroaryldihydropyrimidines or HAP, including compounds named Bay 41-4109, Bay 38-7690
and Bay 39-5493, were discovered in a tissue culture-based ing (Deres K. et al. Science
2003, 893). These HAP s act as synthetic allosteric activators and are able to induce
aberrant capsid formation that leads to degradation of the core protein. HAP analogs also
reorganized core protein from preassembled capsids into noncapsid polymers, presumably by
interaction of HAP with dimers freed during capsid ‘breathing’, the transitory breaking of
individual intersubunit bonds. Bay 41-4109 was administered to HBV ed transgenic mouse
or zed mouse models and demonstrated in vivo efficacy with HBV DNA reduction (Deres
K. et al. Science 2003, 893; Brezillon N. et al. PLoS ONE 2011, e25096). It was also shown that
bis-ANS, a small molecule that acts as a molecular ‘wedge’ and interferes with normal protein
geometry and capsid formation (Zlotnick A. et al. J. Virol. 2002, 4848-4854).
Now, the standard of clinic cure of HBV infection is the loss and/or seroconversion of
HBsAg. Even though N-α and nucleos(t)ide are available to HBV patients, the majority
(around or more than 90%) of treated patients fail to e this goal, which is mainly due to
fact that the current therapies cannot elicit the appearance of lizing antibodies against
HBsAg (anti-HBs), a sign of resolution of HBV infection, in most chronically infected patients.
Hence, there is certainly a medical need for treatments with improved s rate of inducing
HBsAg loss and/or seroconversion and promoting the production of anti-HBs. It is an object of
the invention to go some way s meeting this need, and/or to at least provide the public
with a useful choice.
SUMMARY OF THE INVENTION
The t invention relates to a pharmaceutical ition comprising a TLR7 agonist
and an HBV capsid assembly inhibitor, in a pharmaceutically acceptable carrier. The “TLR7
t” herein is a compound of formula (I), (II) or any one of the compounds disclosed in
patent WO2006/066080, particularly the “TLR7 agonist” herein is [(1S)[(2S,4R,5R)(5-
aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-tetrahydrofuranyl]propyl] acetate;
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate; 5-amino(3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-
d]pyrimidinone; 5-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-
d]pyrimidinone or 5-amino(3’-deoxy-β-D-ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-
2,7-dione, or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. The HBV
capsid assembly inhibitor herein is a compound of formula (III) or any one of the compounds
disclosed in patent WO2014/037480, and WO2015/132276, particularly the
HBV capsid assembly inhibitor herein is S)[[(4R)(2-chlorofluoro-phenyl)
ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; 3-[(8aS)[[(4S)ethoxycarbonyl
(3-fluoromethyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo
[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; ,3S,5S)
[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-1,4-dihydropyrimidin
yl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid; 2-[(1S,3R,5R)[[(4R)(2-
chlorofluoro-phenyl)methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-
6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid; or (S)[(R)(2-Chlorofluorophenyl
)methoxycarbonylthiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholine
carboxylic acid; or pharmaceutically acceptable salt, enantiomer or reomer thereof.
In a first aspect, the ion provides a pharmaceutical composition sing a TLR7
agonist and an HBV capsid assembly inhibitor, in a pharmaceutically acceptable carrier, wherein
the TLR7 agonist is selected from
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-
ydrofuranyl]propyl] acetate having the structure
-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H-
thiazolo[4,5-d]pyrimidine-2,7-dione having the structure
;
and wherein the HBV capsid assembly inhibitor is selected from
3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid having the structure
3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
opyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid having the structure
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
In a second aspect, the invention provides a kit sing a container comprising a TLR7
agonist and an HBV capsid ly inhibitor, wherein the TLR7 agonist is selected from
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-
tetrahydrofuranyl]propyl] acetate having the structure
; or
-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H-
thiazolo[4,5-d]pyrimidine-2,7-dione having the structure
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; and
wherein the HBV capsid assembly inhibitor is selected from
3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid having the structure
; or
3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid having the structure
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
In a third aspect, the invention provides use of a combination of a TLR7 agonist and a
HBV capsid ly tor, selected from the group ting of:
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)-
5-ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo
[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
1-[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro-
2-methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo
]pyrazinyl]-2,2-dimethyl-propanoic acid;
5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H-
thiazolo[4,5-d]pyrimidine-2,7-dione and S)[[(4R)(2-chlorofluoro-phenyl)-
-ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo
]pyrazinyl]-2,2-dimethyl-propanoic acid;
5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H-
thiazolo[4,5-d]pyrimidine-2,7-dione and S)[[(4S)ethoxycarbonyl(3-
fluoromethyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-
,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof,
in the manufacture of one or more ment for the treatment or prophylaxis of hepatitis B
virus infection.
In the description in this specification nce may be made to subject matter which is not
within the scope of the appended claims. That subject matter should be readily identifiable by a
person skilled in the art and may assist in putting into practice the invention as defined in the
appended claims.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1: HBV DNA and HBsAg levels from mice sera in AAV-HBV mouse model.
Results were shown in Figure. 1 for mice with sustained level of HBV DNA and HBsAg treated
with vehicle (shown as diamond), Compound 1 alone at 100mg/kg (shown as circle), Compound
2 alone at 12mg/kg (shown as triangle), or combination of Compound 1 and Compound 2
(shown as square). Relative reduction of HBV DNA and HBsAg post treatment was calculated
by normalizing to their levels in the vehicle group as a base line. Synergistic antiviral effect in
reducing HBsAg was observed in mice treated with the combination therapy, and more
importantly, reduction in HBV DNA and HBsAg was sustained during a 2-week off-treatment
period post the combination therapy. LLQ: lower limit of quantification.
Figure 2: X-ray crystal structure of Compound 2A-2a.
Figure 3: X-ray crystal structure of Compound 3J.
Figure 4: HBV DNA and HBsAg in the AAV-HBV infected mice treated with vehicle,
Compound 1 (100mg/kg), Compound 4 (20mg/kg), or the combination of nd 1 plus
Compound 4. The treatment started after the mice were infected with AAV-HBV for 4 weeks.
They were given the treatment for 6 weeks, and were monitored for another 6-week atment
period. HBV DNA and HBsAg in mouse serum were measured on the indicated time
points by RT-qPCR and HBsAg CLIA, respectively. The results were ted as mean ± SEM.
LLQ: lower limit of quantification.
Figure 5: HBV DNA and HBsAg in the AAV-HBV infected mice treated with e,
Compound 3 (30mg/kg), Compound 4 (20mg/kg), or the combination of Compound 3 plus
Compound 4. The treatment d after the mice were infected with AAV-HBV for 4 weeks.
They were given the treatment for 6 weeks, and were monitored for another 6-week offtreatment
period. HBV DNA and HBsAg in mouse serum were measured on the indicated time
points by RT-qPCR and HBsAg CLIA, respectively. The results were presented as mean ± SEM.
LLQ: lower limit of quantification.
Figure 6: HBV DNA and HBsAg in the AAV-HBV infected mice treated with vehicle,
Compound 1 /kg), Compound 5 (12mg/kg), or the combination of nd 1 plus
Compound 5. The treatment started after the mice were infected with AAV-HBV for 4 weeks.
They were given the treatment for 6 weeks, and were monitored for r 6-week offtreatment
period. HBV DNA and HBsAg in mouse serum were measured on the indicated time
points by RT-qPCR and HBsAg CLIA, respectively. The results were presented as mean ± SEM.
LLQ: lower limit of quantification.
Figure 7: The level of anti-HBs antibody ody against HBsAg ) in the serum of each
mouse taking the single or combination treatment as described in Figures 4, 5, and 6. The serum
samples were collected on day 24 post the removal of treatment and anti-HBs was measured by
anti-HBs CLIA. LLQ: lower limit of quantification.
Figure 8: HBV DNA and HBsAg in the AAV-HBV infected mice treated with vehicle,
Compound 8 (300mg/kg), Compound 4 (20mg/kg), or the combination of nd 8 plus
Compound 4. The treatment started after the mice were infected with AAV-HBV for at least 38
days. They were given the treatment for 6 weeks, and were monitored for another 6-week off-
treatment period. HBV DNA and HBsAg in mouse serum were measured on the indicated time
points by RT-qPCR and HBsAg CLIA, respectively. The results were presented as mean ± SEM.
LLQ: lower limit of quantification.
Figure 9: HBV DNA and HBsAg in the AAV-HBV infected mice treated with e,
Compound 8 (300mg/kg), Compound 10 (20mg/kg), or the combination of Compound 8 plus
Compound 10. The treatment started after the mice were infected with AAV-HBV for at least 38
days. They were given the treatment for 6 weeks, and were monitored for another 6-week offtreatment
period. HBV DNA and HBsAg in mouse serum were measured on the indicated time
points by RT-qPCR and HBsAg CLIA, respectively. The results were presented as mean ± SEM.
LLQ: lower limit of quantification.
Figure 10: HBV DNA and HBsAg in the AAV-HBV ed mice treated with e,
Compound 1 (100mg/kg), nd 10 (20mg/kg), or the combination of Compound 1 plus
Compound 10. The treatment started after the mice were infected with V for at least 38
days. They were given the ent for 6 weeks, and were monitored for another 6-week offtreatment
period. HBV DNA and HBsAg in mouse serum were measured on the indicated time
points by RT-qPCR and HBsAg CLIA, respectively. The results were presented as mean ± SEM.
LLQ: lower limit of quantification.
Figure 11: The level of anti-HBs antibody (antibody against HBsAg ) in the serum of each
mouse taking the single or combination treatment as described in Figures 8, 9, and 10. The serum
samples were collected on day 31 post the removal of ent and anti-HBs was measured by
Bs CLIA. LLQ: lower limit of quantification.
DETAILED DESCRIPTION OF THE ION
Unless defined ise, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which this invention
pertains.
As used herein, the term “C1-6alkyl” refers to a monovalent linear or branched ted
hydrocarbon group of 1 to 6 carbon atoms. In particular embodiments, C1-6alkyl has 1 to 6
carbon atoms, and in more particular embodiments 1 to 4 carbon atoms. Examples of C1-6alkyl
include methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl or tert-butyl.
As used herein, the term “halo” or “halogen” are used interchangeably herein and refer to
fluoro, chloro, bromo, or iodo.
As used herein, the term lkoxy” refers to a group of C1-6alkyl-O-, wherein the “C1-
6alkyl” is as defined above; for example methoxy, ethoxy, propoxy, iso-propoxy, n-butoxy, iso-
butoxy, 2-butoxy, tert-butoxy and the like. Particular lkoxy” groups are methoxy and
ethoxy and more particularly methoxy.
As used herein, the term ycloalkyl” refers to a saturated carbon ring containing from
3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, eptyl and the like. Particular “C3-7cycloalkyl” groups are
cyclopropyl, cyclopentyl and cyclohexyl.
As used herein, the term “C2-6alkenyl” refers to an unsaturated, linear or branched chain
alkenyl group containing 2 to 6, ularly 2 to 4 carbon atoms, for example vinyl, propenyl,
allyl, butenyl and the like. Particular “C2-6alkenyl” group is allyl.
As used herein, the term “C2-6alkynyl” refers to an unsaturated, linear or ed chain
alkynyl group ning 2 to 6, particularly 2 to 4 carbon atoms, for example l, 1-
propynyl, propargyl, butynyl and the like. ular “C2-6alkynyl” groups are ethynyl, 1-
propynyl and propargyl.
As used herein, the term “heterocyclic” ring or “heterocyclyl” refers to a saturated or partly
unsaturated monocyclic or bicyclic ring containing from 3 to 10 ring atoms which can comprise
one, two or three atoms selected from nitrogen, oxygen and/or sulfur. Examples of monocyclic
heterocyclyl rings containing in particular from 3 to 7 ring atoms include, but not limited to,
aziridinyl, azetidinyl, oxetanyl, dinyl, piperazinyl, azepinyl, diazepanyl, pyrrolidinyl,
morpholinyl, dihydrofuryl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl and
thiomorpholinyl. Bicyclic heterocyclyl can be bicyclic fused ri ng or bicyclic bridged ring.
Examples for bicyclic heterocyclyl are bicyclo[3.2.1]octy l, quinuclidinyl, 8-oxaaza-
o[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxaaza-bicyclo[3.3.1]nonyl, 3-thiaaza-
bicyclo[3.3.1]nonyl, or difluoroazabicyclo[3.2.1]octyl. Monocyclic and bicyclic heterocyclyl can
be further substituted by halogen, C1-6 alkyl, cyano, carboxy, carboxyC1-6alkyl.
The term “heterocyclic amino” refers to an amino group with the en atom on the
heterocyclic ring, wherein “heterocyclic” ring is as defined above.
As used herein, the term “diastereomer” refers to a stereoisomer with two or more centers
of chirality and whose les are not mirror images of one another. Diastereomers have
ent physical properties, e.g. melting points, g points, spectral ties, activities and
reactivities.
As used herein, the term “enantiomers” refers to two stereoisomers of a compound which
are non-superimposable mirror images of one another.
As used herein, the term aceutically acceptable salts” refers to salts which are not
ically or otherwise undesirable. Pharmaceutically acceptable salts include both acid and
base addition salts.
As used herein, the term “prodrug” refers to a form or derivative of a compound which is
lized in vivo, e.g., by ical fluids or enzymes by a subject after administration, into a
pharmacologically active form of the compound in order to produce the desired pharmacological
effect. Prodrugs are described e.g. in the Organic Chemistry of Drug Design and Drug Action by
Richard B. Silverman, Academic Press, San Diego, 2004, Chapter 8 Prodrugs and Drug Delivery
Systems, pp. 497-558.
The term “pharmaceutically acceptable acid addition salt” refers to those pharmaceutically
acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and c acids selected from
aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of
organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic
acid, pyruvic acid, oxalic acid, malic acid, maleic acid, maloneic acid, succinic acid, fumaric
acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic
acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid,
ethanesulfonic acid, enesulfonic acid, and clic acid.
The term “pharmaceutically acceptable base addition salt” refers to those pharmaceutically
able salts formed with an organic or inorganic base. Examples of acceptable inorganic
bases include sodium, ium, ammonium, calcium, magnesium, iron, zinc, copper,
manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic
nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines
including naturally occurring substituted amines, cyclic amines and basic ion exchange resins,
such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine,
ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine,
histidine, ne, procaine, amine, choline, betaine, ethylenediamine, amine,
methylglucamine, theobromine, purines, piperizine, dine, N-ethylpiperidine, and polyamine
resins.
Compounds of the general formula (I) which contain one or several chiral centers can
either be present as racemates, diastereomeric es, or optically active single isomers. The
racemates can be separated according to known methods into the enantiomers. Particularly,
diastereomeric salts which can be separated by crystallization are formed from the racemic
mixtures by reaction with an lly active acid such as e.g. D- or L-tartaric acid, mandelic
acid, malic acid, lactic acid or camphorsulfonic acid.
As used herein, “combo” refers to ation.
As used herein, “RT-PCR” refers to Reverse transcription rase chain reaction.
As used , “CLIA” refers to chemiluminescence immunoassay.
As used herein, “AAV” refers to adeno-associated virus.
As used , “AAV-HBV” refers to a recombinant virus that carries 1.3 copies of the
HBV genome packaged in AAV capsids. A chronicle HBV infection mouse model can be
established by injecting mice with AAV-HBV through tail vein injection. In this mouse model,
active HBV replication results in persist HBV viral markers (e.g., HBV DNA, HBsAg, HBeAg,
etc.).
As used herein, “HBsAg” refers to hepatitis B surface antigen.
As used herein, “HBeAg” refers to hepatitis B e antigen.
As used herein, “anti-HBs” refers to antibodies against HBsAg.
As used herein, “HBV specific primers” refers to a pair of -stranded nucleic acid that
serves as ng and ending points for specific amplification of HBV DNA regions.
As used herein, “TLR7” refers to the Toll-like receptor 7 of any species of origin (e.g.,
human, murine, woodchuck etc.).
As used herein, “TLR7 agonist” refers to a compound that acts as an agonist of TLR7.
Unless otherwise indicated, a TLR7 agonist can include the compound in any pharmaceutically
acceptable form, including any isomer (e.g., diastereomer or enantiomer), salt, solvate,
polymorph, and the like. The TLR agonism for a particular compound may be determined in any
suitable manner. For example, assays for detecting TLR agonism of test compounds are
bed, for example, in U.S. Provisional Patent Application Ser. No. 60/432,650, filed Dec.
11, 2002, and recombinant cell lines suitable for use in such assays are described, for example, in
U.S. Provisional Patent Application Ser. No. 60/432,651, filed Dec. 11, 2002.
The term ising” as used in this specification and claims means “consisting at least
in part of”. When interpreting statements in this specification and claims which include the term
ising”, other features besides the features prefaced by this term in each statement can also
be present. Related terms such as “comprise” and ises” are to be interpreted in similar
manner.
The present invention relates to a pharmaceutical ition comprising a TLR7 agonist
and an HBV capsid assembly tor, in a pharmaceutically acceptable r.
In one embodiment of present invention and/or described herein, a “TLR7 agonist” is a
compound of formula (I):
(I),
wherein
R1 is hydroxy, C1-6alkyl, haloC1-6alkyl, C1-6alkylcarbonyl-O-, C1-6alkyl-S-, azido, cyano,
C2-6alkenyl, C1-6alkylsulfonyl-NH-, (C1-6alkyl)2N-, C1-6alkylcarbonyl-NH- or heterocyclic amino;
R2 is hydrogen, C1-6alkyl, koxyC1-6alkyl, C3-7cycloalkyl, C2-6alkynyl, C2-6alkenyl,
benzyl and thiophenyl;
R3 is hydrogen or C1-6alkylcarbonyl;
or pharmaceutically acceptable salt, enantiomer or reomer thereof;
In another embodiment of present invention and/or described herein, a “TLR7 agonist” is a
compound of formula (II):
(II),
wherein
R4 and R5 are independently selected from hydrogen, C2-6alkenyl and C1-6alkyl;
R6 and R7 are independently selected from hydrogen, C1-6alkyl, C3-7cycloalkyl, C3-
7cycloalkylC2-6alkynyl, kenyl, C2-6alkynyl and phenyl;
R8 is hydrogen or C1-6alkylcarbonyl;
or pharmaceutically able salt, enantiomer or diastereomer thereof.
More particularly, the TLR7 agonist according to present invention and/or described herein
s to [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate; [(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidin-
3-yl)-1,3-oxathiolanyl]-cyclopropyl-methyl] acetate; 5-amino(3’-deoxy-β-D-
ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone; 5-amino(2’-O-acetyl-3’-deoxy-β-D-
ranosyl)-3H-thiazolo[4,5-d]pyrimidinone; 5-amino(3’-deoxy-β-D-ribofuranosyl)-
3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione; or [(2R,3R,5S)[(1S)acetoxypropyl](5-
amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidinyl)tetrahydrofuranyl] acetate ;or
pharmaceutically able salt, enantiomer or diastereomer thereof. In another embodiment, a
“TLR7 agonist” also relates to anyone of the compounds disclosed in patent WO2006/066080.
After administration, compounds of formula (I) or a (II) or compounds in patent
WO2006/066080 are metabolized into their active forms which are useful TLR7 agonists.
As used herein, “hepatitis B virus” or “HBV” refers to a member of the Hepadnaviridae
family having a small double-stranded DNA genome of approximately 3,200 base pairs and a
tropism for liver cells. “HBV” includes hepatitis B virus that infects any of a variety of
mammalian (e.g., human, non-human primate, etc.) and avian (duck, etc.) hosts. “HBV” includes
any known HBV genotype, e.g., serotype A, B, C, D, E, F, and G; any HBV pe or HBV
subtype; any HBV isolate; HBV ts, e.g., HBeAg-negative variants, drug-resistant HBV
variants (e.g., lamivudine-resistant variants; adefovir-resistant mutants; vir-resistant
mutants; entecavir-resistant mutants; etc.); and the like.
As used herein, “HBV capsid ly inhibitor” refers to a compound that inhibits and/or
disrupt and/or accelerates and/or s and/or delays and or reduces and/or modifies normal
HBV capsid assembly (e.g., during maturation) and/or normal capsid disassembly (e.g., during
infectivity) and/or perturbs capsid stability, thereby inducing aberrant capsid morphology and
function.
In one embodiment of present invention and/or described herein, the HBV capsid assembly
inhibitor is a compound of formula (III):
(III),
wherein
R9 is C1-6alkyl;
R10 is phenyl, which is once or twice or three times substituted by n or C1-6alkyl;
R11 is hydrogen or C1-6alkyl;
R12 is monocyclic, bicyclic fused or bicyclic d heterocyclyl;
or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
More particularly the HBV capsid assembly tor according to present invention and/or
described herein relates to 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonyl
thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-
a]pyrazinyl]-2,2-dimethyl-propanoic acid; 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro
methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; 2-[(1R,3S,5S)[[(4R)(2-chloro
fluoro-phenyl)methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-
roazabicyclo[3.2.1]octanyl]acetic acid; 2-[(1S,3R,5R)[[(4R)(2-chlorofluorophenyl
)methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid (disclosed in patent ); or (S)[(R)
(2-Chlorofluoro-phenyl)methoxycarbonylthiazolyl-3,6-dihydro-pyrimidin
ylmethyl]-morpholinecarboxylic acid; or pharmaceutically able salt, omer or
reomer thereof. In another embodiment, an “HBV capsid assembly inhibitor” more
particularly is anyone of the compounds disclosed in patent WO2015/132276,
and WO2014/037480.
In one embodiment of t invention and/or described herein, the pharmaceutical
composition ses a TLR7 agonist and an HBV capsid assembly inhibitor, wherein TLR7
agonist and HBV capsid assembly inhibitor are independently selected from Table 1:
(Compound 2 and 4 were disclosed in patent WO2015/132276; Compound 5 and 6 were
disclosed in patent WO2014/184328; Compound 7, 8 and 9 were disclosed in patent
WO2006/066080; Compound 10 was disclosed in patent WO2014/037480).
Table 1. List of TLR7 agonist and HBV capsid
Entry Class Compound Name Structure
[(1S)[(2S,4R,5R)(5-amino-
2-oxo-thiazolo[4,5-d]pyrimidin-
TLR7
Compound 1 3-yl)hydroxyagonist
tetrahydrofuranyl]propyl]
acetate
3-[(8aS)[[(4R)(2-chloro
fluoro-phenyl)
ethoxycarbonylthiazolyl-
HBV capsid 1,4-dihydropyrimidin
Compound 2
inhibitor
yl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo
[1,5-
zinyl]-2,2-dimethylpropanoic
acid
[(S)-[(2S,5R)(5-aminooxo-
TLR7 thiazolo[4,5-d]pyrimidinyl)-
Compound 3
agonist 1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate
3-[(8aS)[[(4S)
carbonyl(3-fluoro
methyl-phenyl)thiazolyl-
HBV capsid 1,4-dihydropyrimidin
Compound 4
inhibitor yl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo
[1,5-
zinyl]-2,2-dimethylpropanoic
acid
2-[(1R,3S,5S)[[(4R)(2-
chlorofluoro-phenyl)
methoxycarbonylthiazolyl-
HBV capsid
Compound 5 1,4-dihydropyrimidin
inhibitor
yl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octan
yl]acetic acid
2-[(1S,3R,5R)[[(4R)(2-
chlorofluoro-phenyl)
methoxycarbonylthiazolyl-
HBV capsid
nd 6 1,4-dihydropyrimidin
inhibitor
yl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octan
yl]acetic acid
-amino(3’-deoxy-β-DTLR7
Compound 7 ranosyl)-3H-thiazolo[4,5-
d]pyrimidinone
-amino(2’-O-acetyl-3’-
TLR7
Compound 8 deoxy-β-D-ribofuranosyl)-3H-
agonist
thiazolo[4,5-d]pyrimidinone
-amino(3’-deoxy-β-DTLR7
ribofuranosyl)-3H,6HCompound
agonist thiazolo[4,5-d]pyrimidin-2,7-
dione
(S)[(R)(2-Chlorofluoro-
O Cl
phenyl)methoxycarbonyl
HBV capsid
Compound 10 thiazolyl-3,6-dihydro- O N
inhibitor
pyrimidinylmethyl]- S
O N
morpholinecarboxylic acid H
N N
[(2R,3R,5S)[(1S)
acetoxypropyl](5-amino-2,7-
TLR7
Compound 11 dioxo-6H-thiazolo[4,5-
agonist
d]pyrimidin
yl)tetrahydrofuranyl] acetate
More particularly, the present invention and/or sure relates to a ceutical
composition comprising a TLR7 agonist and an HBV capsid assembly inhibitor which is selected
from any one of the following combinations:
Compound 1 and Compound 2; Compound 1 and Compound 4;
Compound 1 and Compound 5; Compound 1 and Compound 6;
Compound 1 and Compound 10; Compound 3 and Compound 2;
Compound 3 and Compound 4; Compound 3 and Compound 5;
Compound 3 and Compound 6; nd 3 and Compound 10;
Compound 7 and Compound 2; Compound 7 and Compound 4;
Compound 7 and Compound 5; Compound 7 and nd 6;
Compound 7 and Compound 10; Compound 8 and Compound 2;
Compound 8 and Compound 4; Compound 8 and Compound 5;
Compound 8 and Compound 6; Compound 8 and Compound 10;
nd 9 and Compound 2; Compound 9 and Compound 4;
nd 9 and Compound 5; Compound 9 and Compound 6;
Compound 9 and Compound 10; Compound 11 and nd 2;
Compound 11 and Compound 4; Compound 11 and nd 5;
Compound 11 and Compound 6; and Compound 11 and Compound 10.
The Compound 1 to 11 of the above said combination can be replaced by its corresponding
pharmaceutically acceptable salt, enantiomer or diastereomer.
The Compound 1 of the above said combination can be replaced by its corresponding
mono, double or triple prodrugs, such as:
, , ,
, , , and
their pharmaceutically acceptable salt, enantiomer or diastereomer.
In one embodiment of present invention and/or described herein, the pharmaceutical
composition consists of a TLR7 agonist and an HBV capsid assembly tor, in a
pharmaceutically acceptable r. More ularly, the ition consists of:
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)
ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro
methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 2-[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)
methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-
tetrahydrofuranyl]propyl] acetate and 2-[(1S,3R,5R)[[(4R)(2-chlorofluoro-phenyl)
methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid;
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] e and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)
ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethylphenyl
)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate and 2-[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)
methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid;
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate and 2-[(1S,3R,5R)[[(4R)(2-chlorofluoro-phenyl)
ycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-
tetrahydrofuranyl]propyl] acetate and (S)[(R)(2-Chlorofluoro-phenyl)
methoxycarbonylthiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholinecarboxylic
acid;
(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate and (S)[(R)(2-Chlorofluoro-phenyl)methoxycarbonyl
thiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholinecarboxylic acid;
-amino(3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone and (S)
[(R)(2-Chlorofluoro-phenyl)methoxycarbonylthiazolyl-3,6-dihydro-pyrimidin
ylmethyl]-morpholinecarboxylic acid;
-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and (S)[(R)(2-Chlorofluoro-phenyl)methoxycarbonylthiazolyl-3,6-dihydropyrimidinylmethyl
]-morpholinecarboxylic acid;
-amino(3’-deoxy-β-D-ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione and
(S)[(R)(2-Chlorofluoro-phenyl)methoxycarbonylthiazolyl-3,6-dihydropyrimidinylmethyl
]-morpholinecarboxylic acid;
-amino(3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone and 3-[(8aS)-
7-[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4-dihydropyrimidin
yl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic
acid;
-amino(3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone and 3-[(8aS)-
7-[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-dihydropyrimidin
yl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic
acid;
5-amino(3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone and 2-
[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid;
-amino(3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone and 2-
[(1S,3R,5R)[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid;
-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and S)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid;
5-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and S)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid;
-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and 2-[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid;
-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and 2-[(1S,3R,5R)[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid;
-amino(3’-deoxy-β-D-ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione and 3-
[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid;
-amino(3’-deoxy-β-D-ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione and 3-
[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
opyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid;
5-amino(3’-deoxy-β-D-ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione and 2-
[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid; or
-amino(3’-deoxy-β-D-ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione and 2-
[(1S,3R,5R)[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid; in a
pharmaceutically able carrier.
In another embodiment of present ion and/or described herein, the pharmaceutical
composition consists of a TLR7 agonist and an HBV capsid assembly inhibitor, in a
pharmaceutically acceptable carrier, most particularly, the composition consists of:
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)
ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro
methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethylphenyl
)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
o[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
1-[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-
tetrahydrofuranyl]propyl] acetate and 2-[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)
methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] e and (S)[(R)(2-Chlorofluoro-phenyl)
methoxycarbonylthiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholinecarboxylic
acid;
-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid;
-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and (S)[(R)(2-Chlorofluoro-phenyl)methoxycarbonylthiazolyl-3,6-dihydropyrimidinylmethyl
]-morpholinecarboxylic acid;
[(2R,3R,5S)[(1S)acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidin-
3-yl)tetrahydrofuranyl] acetate and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)
ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(2R,3R,5S)[(1S)acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidin-
3-yl)tetrahydrofuranyl] e and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-
)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(2R,3R,5S)[(1S)acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidin-
3-yl)tetrahydrofuranyl] acetate and 2-[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)
methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid;
[(2R,3R,5S)[(1S)acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidin-
3-yl)tetrahydrofuranyl] acetate and 2-[(1S,3R,5R)[[(4R)(2-chlorofluoro-phenyl)
methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid; or
[(2R,3R,5S)[(1S)acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidin-
etrahydrofuranyl] e and (S)[(R)(2-Chlorofluoro-phenyl)
methoxycarbonylthiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholinecarboxylic
acid; in a pharmaceutically acceptable carrier.
In another embodiment of present invention, other TLR7 agonists or HBV capsid assembly
tors can also be used in the pharmaceutical composition including small molecules or large
molecules. es of other TLR7 agonists include, but not limited to, mod, Resiquimod,
PF-4878691, SM-276001, ANA975, ANA773 and GS9620. Examples of other HBV capsid
assembly inhibitors include, but not limited to, Bay 41-4109, Bay 38-7690, Bay 39-5493, GLS4,
AT-61 and .
In another embodiment of t invention, the pharmaceutical composition can
additionally comprise one or more other antiviral agents, which include, but not limited to,
lamivudine, adefovir, tenofovir, telbivudine and entecavir.
Typical dosages of a TLR7 agonist and/or an HBV capsid assembly inhibitor can be in the
ranges recommended by the manufacturer, and where indicated by in vitro ses in an
animal models, can be reduced by up to about one order of magnitude concentration or amount.
Thus, the actual dosage will depend upon the judgment of the physician, the condition of the
patient, and the effectiveness of the therapeutic method based on the in vitro responsiveness of
the appropriate animal models.
Described herein is a method for manufacturing a medicament for treatment or prophylaxis
of hepatitis B virus infection, characterized in that a TLR7 agonist and an HBV capsid assembly
inhibitor are used in the medicament.
Described herein is the method for manufacturing a medicament for treatment or
prophylaxis of hepatitis B virus infection, terized in that the TLR7 agonist and the HBV
capsid assembly tor are co-administered in the same formulation or different formulation.
For purposes of the present invention, minister” refers to any administration of the
TLR7 agonist and the HBV capsid assembly inhibitor as the two active , either tely
or together, where the two active agents are administered as part of an appropriate dose regimen
designed to obtain the benefit of the combination therapy. Thus, the two active agents can be
administered either as part of the same pharmaceutical composition or in separate
pharmaceutical compositions. Also, the two active agents can be administered either at the same
time, or sequentially.
The TLR7 agonist and the HBV capsid assembly inhibitor can be administered with
various pharmaceutically acceptable inert rs in the form of tablets, capsules, lozengens,
troches, hard s, powders, sprays, creams, , itories, s, gels, pastes, lotions,
ointments, elixirs, syrups, and the like. Administration of such dosage forms can be carried out in
single or multiple doses. Carries include solid diluents of fillers, sterile aqueous media and
various non-toxic organic solvents. Administration of such dosage forms can be carried out
through, but not limited to, oral stration, parenteral administration, veterinary
administration.
Described herein is the method for manufacturing a medicament for treatment or
prophylaxis of tis B virus infection, characterized in that the TLR7 agonist and the HBV
capsid assembly inhibitor are intended for administration to a subject by the same route or
different routes.
Described herein is the method for manufacturing a medicament for treatment or
laxis of hepatitis B virus infection, characterized in that the TLR7 agonist and the HBV
capsid assembly inhibitor are intended for administration to a subject by parenteral or oral
administration.
Described herein is the method for manufacturing a medicament for treatment or
laxis of hepatitis B virus infection, characterized in that the administration of TLR7
agonist and the HBV capsid assembly inhibitor to a subject is simultaneous or sequential. In any
of the methods described herein, the administration of agents simultaneously can be performed
by separately or sequentially administering agents at the same time, or together as a fixed
combination. Also, in any of the methods described , the administration of agents
separately or sequentially can be in any order.
Described herein is the method for manufacturing a ment for treatment or
prophylaxis of hepatitis B virus infection, characterized in that TLR7 agonist thereof is a
compound of formula (I) or formula (II), or pharmaceutically acceptable salt, enantiomer or
diastereomer thereof. Particularly, the TLR7 t is [(1S)[(2S,4R,5R)(5-aminooxothiazolo
[4,5-d]pyrimidinyl)hydroxy-tetrahydrofuranyl]propyl] acetate; [(S)-[(2S,5R)
(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-cyclopropyl-methyl] acetate;
-amino(3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone; 5-amino(2’-O-
acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone; 5-amino(3’-deoxy-β-
D-ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione; or [(2R,3R,5S)[(1S)
acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidinyl)tetrahydrofuranyl]
acetate ; or pharmaceutically acceptable salt, omer or diastereomer thereof.
Described herein is the method for manufacturing a ment for treatment or
prophylaxis of hepatitis B virus infection, characterized in that the HBV capsid assembly
inhibitor thereof is a compound of formula (III), or pharmaceutically acceptable salt, enantiomer
or diastereomer f. Particularly, the HBV capsid assembly inhibitor is
3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid;
3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid;
2-[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-
1,4-dihydropyrimidinyl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid;
2-[(1S,3R,5R)[[(4R)(2-chlorofluoro-phenyl)methoxycarbonylthiazolyl-
1,4-dihydropyrimidinyl]methyl]-6,6-difluoroazabicyclo[3.2.1]octanyl]acetic acid;
or (S)[(R)(2-Chlorofluoro-phenyl)methoxycarbonylthiazolyl-3,6-
dihydro-pyrimidinylmethyl]-morpholinecarboxylic acid;
or pharmaceutically able salt, enantiomer or diastereomer thereof.
bed herein is the method for manufacturing a medicament for treatment or
prophylaxis of hepatitis B virus infection, characterized in that the medicament additionally
comprising one or more other antiviral agents, which include, but not limited to, lamivudine,
adefovir, tenofovir, udine and entecavir.
Described herein is the method for manufacturing a medicament for treatment or
prophylaxis of hepatitis B virus infection, wherein the TLR7 agonist and the HBV capsid
assembly inhibitor used in the medicament are:
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)
ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro
methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate and S)[[(4S)ethoxycarbonyl(3-fluoromethylphenyl
iazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
1-[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 2-[(1R,3S,5S)[[(4R)(2-chlorofluoro-phenyl)
methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
l] e and (S)[(R)(2-Chlorofluoro-phenyl)
methoxycarbonylthiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholinecarboxylic
acid;
5-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid; or
-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and (S)[(R)(2-Chlorofluoro-phenyl)methoxycarbonylthiazolyl-3,6-dihydropyrimidinylmethyl
]-morpholinecarboxylic acid;in a pharmaceutically acceptable carrier.
Another embodiment of present invention and/or described herein relates to a kit
comprising a container comprising a TLR7 agonist and an HBV capsid ly inhibitor, said
kit can further comprise a sterile diluent.
A further embodiment of present invention s to the said kit, wherein the kit can
further comprise a package insert comprising printed instructions directing the use of a combined
treatment of a TLR7 t and an HBV capsid ly inhibitor as a method for treatment or
prophylaxis of hepatitis B virus infection.
Another embodiment of present invention and/or described herein relates to the said kit,
wherein the TLR7 t is [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidin
yl)hydroxy-tetrahydrofuranyl]propyl] acetate; [(S)-[(2S,5R)(5-aminooxothiazolo
[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-cyclopropyl-methyl] acetate; 5-amino(3’-
β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone; 5-amino(2’-O-acetyl-3’-
deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone; 5-amino(3’-deoxy-β-D-
ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione; or [(2R,3R,5S)[(1S)
acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidinyl)tetrahydrofuranyl]
acetate; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; and/or the HBV
capsid assembly inhibitor is 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonyl
thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-
a]pyrazinyl]-2,2-dimethyl-propanoic acid; 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro
methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; 2-[(1R,3S,5S)[[(4R)(2-chloro
fluoro-phenyl)methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-
difluoroazabicyclo[3.2.1]octanyl]acetic acid; 2-[(1S,3R,5R)[[(4R)(2-chloro
fluoro-phenyl)methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-
difluoroazabicyclo[3.2.1]octanyl]acetic acid; or (S)[(R)(2-Chlorofluoro-phenyl)
methoxycarbonylthiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholinecarboxylic
acid; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
Another embodiment of present invention and/or described herein relates to the said kit,
wherein the TLR7 agonist and the HBV capsid assembly inhibitor used in the container are:
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)
carbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro
methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
o[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate and S)[[(4S)ethoxycarbonyl(3-fluoromethylphenyl
)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and ,3S,5S)[[(4R)(2-chlorofluoro-phenyl)
ycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid;
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl
]propyl] acetate and (S)[(R)(2-Chlorofluoro-phenyl)
methoxycarbonylthiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholinecarboxylic
acid;
o(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid; or
5-amino(2’-O-acetyl-3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone
and (S)[(R)(2-Chlorofluoro-phenyl)methoxycarbonylthiazolyl-3,6-dihydropyrimidinylmethyl
]-morpholinecarboxylic acid;in a pharmaceutically able carrier.
Described herein is a method for the treatment or prophylaxis of hepatitis B virus infection,
comprising administration to a t with an effective first amount of a TLR7 agonist, or
pharmaceutically acceptable salt, enantiomer or reomer thereof; and a second amount of
HBV capsid ly inhibitor, or pharmaceutically acceptable salt, enantiomer or reomer
thereof; wherein the TLR7 agonist is [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-
d]pyrimidinyl)hydroxy-tetrahydrofuranyl]propyl] acetate; [(S)-[(2S,5R)(5-amino
oxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-cyclopropyl-methyl] acetate; 5-amino-
3-(3’-deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone; 5-amino(2’-O-acetyl-3’-
deoxy-β-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidinone; 5-amino(3’-deoxy-β-D-
ribofuranosyl)-3H,6H-thiazolo[4,5-d]pyrimidin-2,7-dione; or [(2R,3R,5S)[(1S)
acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidinyl)tetrahydrofuranyl]
acetate; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; and/or the HBV
capsid assembly inhibitor is 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonyl
thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-
a]pyrazinyl]-2,2-dimethyl-propanoic acid; 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro
methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-
imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; 2-[(1R,3S,5S)[[(4R)(2-chloro
fluoro-phenyl)methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-
roazabicyclo[3.2.1]octanyl]acetic acid; 2-[(1S,3R,5R)[[(4R)(2-chlorofluorophenyl
)methoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]-6,6-difluoro
azabicyclo[3.2.1]octanyl]acetic acid; or (S)[(R)(2-Chlorofluoro-phenyl)
methoxycarbonylthiazolyl-3,6-dihydro-pyrimidinylmethyl]-morpholinecarboxylic
acid; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof.
Described herein is use of pharmaceutical composition herein mentioned above as an
antiviral medicament, in particular as the medicament for treatment or prophylaxis of tis B
virus infection.
Another embodiment of present ion and/or described herein relates to the use of a
TLR7 agonist and an HBV capsid assembly inhibitor for the manufacture of pharmaceutical
composition herein mentioned above as an antiviral ment, in particular the medicament
for treatment or prophylaxis of hepatitis B virus infection.
EXAMPLES
The invention will be more fully understood by reference to the following es. They
should not, r, be construed as limiting the scope of the invention.
Example 1
[(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-
tetrahydrofuranyl]propyl] acetate (Compound 1)
Compound 1 was prepared through the following scheme:
TsCl MeMgBr
1A 1B 1C
obenzoic acid Ac O
1D 1F
Ac O
HOAc
1G 1H 1I
Preparation of [(2R)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
]dioxolyl]hydroxy-ethyl] 4-methylbenzenesulfonate
To a solution of (1R)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]ethane-1,2-diol (compound 1A, 100 g, 490 mmol) in dry pyridine (1000 mL)
was added p-toluenesulfonyl chloride (139 g, 735 mmol) at 0oC. After being stirred at room
temperature for 12 hours, the resulted solution was quenched by water (100 mL) and
concentrated in vacuo. The residue was purified by column chromatography on silica gel (eluting
with 1:10 to 1:3 EtOAc in petroleum ether) to afford 130 g of [(2R)[(3aR,5S,6aR)-2,2-
dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxolyl]hydroxy-ethyl] 4-
methylbenzenesulfonate (compound 1B) as a slight yellow oil.
Compound 1B: 1H NMR (400 MHz, CDCl3) δ ppm: 7.82 (d, J = 8.00 Hz, 2H), 7.38 (d, J =
8.00 Hz, 2H), 5.78 (d, J = 3.76 Hz, 1H), 4.75 (t, J = 4.00 Hz, 1H), 4.20- 4.12 (m, 2H), 4.03- 3.97
(m, 2H), 2.48 (s, 3H), 2.39 (d, J = 3.51 Hz, 1H), 2.08-2.15 (m, 1 H), 1.75-1.80 (m, 1 H), 1.51 (s,
3 H), 1.33 (s, 3 H).
Preparation of (3aR,5S,6aR)-2,2-dimethyl[(2R)-oxiranyl]-3a,5,6,6atetrahydrofuro
[2,3-d][1,3]dioxole
To a solution of [(2R)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]hydroxy-ethyl] 4-methylbenzenesulfonate (compound 1B, 100 g, 280
mmol) in anhydrous THF (1500 mL) cooled at -70 oC was added potassium
bis(trimethylsilyl)amide (340 mL, 340 mmol, 1 M in THF) under N2 atmosphere. After being
stirred at -70 oC for 1 hour, the reaction mixture was poured into saturated NH4Cl on. The
organic layer was separated and the aqueous phase was extracted with EtOAc. The combined
organic layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified by
column chromatography on silica gel (eluting with 1:3 EtOAc in petroleum ether) to afford 40.5
g of S,6aR)-2,2-dimethyl[(2R)-oxiranyl]-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole
(compound 1C) as a slight yellow oil.
Compound 1C: 1H NMR: (400 MHz, CDCl3) δ ppm: 5.87 (d, J = 3.76 Hz, 1H), 4.77 (t, J
= 4.00, 1H), 4.20-4.28 (m, 1H), 3.14-3.20 (m, 1H), 2.83-2.88 (m, 1H), 2.63 (dd, J = 5.00, 2.80
Hz, 1H), 2.09 (dd, J = 12.00, 4.00 Hz, 1H), .79 (m, 1H), 1.52 (s, 3H), 1.34 (s, 3H).
Preparation of -[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]propanol
To a suspension of CuI (19.3 g, 107 mmol) in dry THF (2000 mL) under N2 atmosphere
was added methyl ium bromide (3 M in l ether, 537 mL, 1.61 mol) at -70 oC. After
being stirred at the same temperature for 1 hour, a solution of S,6aR)-2,2-dimethyl
[(2R)-oxiranyl]-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxole (compound 1C, 100 g, 537 mmol,
dissolved in anhydrous THF 200 mL) was added to reaction mixture dropwise. After being
d at -70 oC for additional 2 hours, the reaction e was poured into saturated NH4Cl
solution. The organic layer was separated and the aqueous phase was extracted with EtOAc
twice. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The
residue was purified by column chromatography on silica gel (eluting with 1:3 EtOAc in
petroleum ether) to afford 82 g of (1R)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6atetrahydrofuro
[2,3-d][1,3]dioxolyl]propanol (compound 1D) as a slight yellow solid.
Compound 1D: 1H NMR (400 MHz, CDCl3) δ ppm: 5.83 (d, J = 3.76 Hz, 1H), 4.81 - 4.73
(m, 1H), 4.26-4.19 (m, 1H), 3.91-3.82 (m, 1H), 2.08-2.02 (m, 1H), 1.93 - 1.89 (m, 1H), 1.54 (s,
3H), 1.49-1.39 (m, 2H), 1.34 (s, 3H), 1.02 (t, J = 7.53 Hz, 3H).
Preparation of [(1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]propyl] 4-nitrobenzoate
To a stirred solution of (1R)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]propanol (compound 1D, 50 g, 245 mmol), triphenylphosphine (195 g, 743
mmol), 4-nitrobenzoic acid (124 g, 743 mmol) in THF (1200 mL) was added diethyl
azodicarboxylate (130 g, 743 mmol) dropwise at 0 oC under N2. After being stirred at 18 oC for
hours, the mixture was quenched by addition of saturated NaHCO3 on and extracted
with EtOAc. The organic layers were combined, dried over Na2SO4 and concentrated in vacuo.
The residue was purified by column chromatography on silica gel ng with 1:3 EtOAc in
petroleum ether) to afford 61 g of [(1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6atetrahydrofuro
[2,3-d][1,3]dioxolyl]propyl] obenzoate (compound 1E) as a slight yellow
solid.
Compound 1E: 1H NMR (400 MHz, CDCl3) δ ppm: 8.34- 8.22 (m, 4 H), 5.85 (d, J = 3.76
Hz, 1H), 5.23- 5.17 (m, 1H), 4.76 (t, J = 4.27 Hz, 1H), 4.48- 4.39 (m, 1H), 2.12 (dd, J = 13.30,
4.52 Hz, 1H), 1.88- 1.78 (m, 2H), 1.71- 1.62 (m, 1H), 1.55 (s, 3 H), 1.34 (s, 3 H), 1.01 (t, J =
7.40 Hz, 3 H).
Preparation of (1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]propanol
To a solution of [(1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]propyl] 4-nitrobenzoate (compound 1E, 100 g, 285 mmol) in methanol (1200
mL) was added K2CO3 (78.7 g, 570 mmol). After being stirred at room temperature for 10
minutes, the resulted mixture was filtered. The filtrate was concentrated in vacuo. The residue
was purified by column chromatography on silica gel (eluting with 1:8 EtOAc in petroleum ether)
to afford 54.7 g of (1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]propanol und 1F) as a slight yellow solid.
Compound 1F: 1H NMR (400 MHz, CDCl3) δ ppm: 5.81 (d, J = 3.64 Hz, 1H), 4.75 (t, J =
4.20 Hz, 1H), 4.18- 4.11 (m, 1H), 3.49-3.40 (m, 1H), 2.07-2.00 (m, 2H), 1.84-1.75 (m, 1H),
1.59- 1.47 (m, 5H), 1.32 (s, 3H), 1.01 (t, J = 7.40 Hz, 3H).
Preparation of [(1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]propyl] acetate
To a d solution of (1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
d][1,3]dioxolyl]propanol (compound 1F,13.5 g, 67 mmol), TEA (81 g, 804 mmol), DMAP
(1.6 g, 13 mmol) in anhydrous DCM (150 mL) was added acetic anhydride (62 g, 603 mmol).
After being stirred at 22 oC for 10 hours, the reaction was quenched by the ted NaHCO3
solution. The organic layer was separated and the s phase was extracted with EtOAc. The
combined organic layers were dried over Na2SO4, and concentrated in vacuo. The residue was
purified by column chromatography on silica gel (eluting with 1:8 EtOAc in petroleum ether) to
afford 13 g of [(1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol
yl]propyl] acetate (compound 1G) as a colourless oil.
Compound 1G: 1H NMR (400 MHz, CDCl3) δ ppm: 5.83 (d, J = 3.76 Hz, 1H), 4.92 (dt, J
= 7.97, 5.18 Hz, 1H), 4.74 (t, J = 4.00 Hz, 1H), 4.35- 4.27 (m, 1H), 2.12 (s, 3H), 2.08 - 1.99 (m,
1H), 1.74- 1.56 (m, 3H), 1.53 (s, 3H), 1.34 (s, 3H), 0.95 (t, J = 7.40 Hz, 3H).
Preparation of [(3R,5S)acetoxy[(1S)acetoxypropyl]tetrahydrofuranyl] acetate
1H
To a solution of [(1S)[(3aR,5S,6aR)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-
]dioxolyl]propyl] acetate (compound 1G, 4.8 g, 20 mmol), acetic acid (12.2 g, 200
mmol) and acetic anhydride (10.2 g, 100 mmol) in anhydrous DCM (100 mL) was added
concentrated H2SO4 (0.5 mL) at 0 oC. After being stirred at 22 oC for 3 hours, the reaction was
quenched by addition of saturated NaHCO3 solution. The organic layer was separated and the
s phase was extracted with EtOAc. The combined c layers were dried over Na2SO4,
filtered, and concentrated in vacuo. The residue was purified by column on silica gel (eluting
with 1:8 EtOAc in petroleum ether) to afford 2.3 g of [(3R,5S)acetoxy[(1S)
acetoxypropyl]tetrahydrofuranyl] acetate (compound 1H) as a colourless oil.
Compound 1H: 1H NMR (400 MHz, CDCl3) δ ppm: 6.12 (s, 1H), 5.19 (d, J = 4.52 Hz,
1H), 4.83- 4.91 (m, 1H), 4.34- 4.44 (m, 1H), 2.09- 2.19 (m, 9H), 1.51- 1.74 (m, 4H), 0.94 (t, J =
7.40 Hz, 3H).
ation of [(2R,3R,5S)[(1S)acetoxypropyl](5-aminooxo-thiazolo[4,5-
d]pyrimidinyl)tetrahydrofuranyl] acetate
To a suspension of 5-amino-3H-thiazolo[4,5-d]pyrimidinone (3.5 g, 20.8 mmol) in
xylene (160 mL) was added BSA (21.2 g, 104 mmol). The reaction mixture was stirred at 70 oC
for 1 hour under argon to form a clear solution. After some of xylene and excrescent BSA were
evaporated, [(3R,5S)acetoxy[(1S)acetoxypropyl]tetrahydrofuranyl] e
(compound 1H, 3.0 g, 10.4 mmol) and TMSOTf (2.6 g, 11.6 mmol) were added in sequence at 0
oC. After being heated with stirring at 65 oC for 2 hours, the reaction was quenched with water
(30 mL), extracted with EA (30 mL) three times. The combined organic layers were dried over
Na2SO4 and concentrated in vacuo. The residue was purified by column on silica gel (eluting
with 1:10 to 1:1 EtOAc in petroleum ether) to give 2.0 g of [(2R,3R,5S)[(1S)
acetoxypropyl](5-aminooxo-thiazolo[4,5-d]pyrimidinyl)tetrahydrofuranyl] acetate
(compound 1I) as a white solid.
Compound 1I: 1H NMR (400 MHz, CDCl3) δ ppm: 8.15 (s, 1 H), 6.04 (d, J = 1.51 Hz, 1
H), 5.80 (d, J = 7.03 Hz, 1 H), 5.27 (br. s., 2 H), 4.98- 5.04 (m, 1 H), 4.32- 4.39 (m, 1 H), 2.63 -
2.77 (m, 1 H), 2.13 (s, 3 H), 2.09 (s, 3 H), 2.00 - 2.07 (m, 1 H), 1.61- 1.75 (m, 2 H), 0.94 (t, J =
7.40 Hz, 3 H).
Preparation of [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)
hydroxy-tetrahydrofuranyl]propyl] acetate
[(2R,3R,5S)[(1S)acetoxypropyl](5-aminooxo-thiazolo[4,5-d]pyrimidin
yl)tetrahydrofuranyl] acetate (compound 1I, 3.2 g, 8.0 mmol) and K2CO3 (2.2 g, 16.0 mmol)
were suspended in anhydrous ethanol (85 mL) at room ature. Methanol (85 mL) was
added dropwise under N2 atmosphere. After the on, the mixture was stirred at room
temperature for 10 minutes (monitored by TLC). After the reaction, the mixture was poured into
te NH4Cl, extracted with EA (150 mL) four times. The combined organic layers were dried
over Na2SO4 concentrated in vacuo. The residue was purified by column on silica gel (eluting
with 1:100 to 1:70 MeOH in DCM) to give the crude product, which was further purified by
flash column (eluting with acetonitrile and water) to give 1.64 g of 1-[(2S,4R,5R)(5-
aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-tetrahydrofuranyl]propyl] acetate
(Compound 1) as a white power.
Compound 1: 1H NMR (400 MHz, Methanol-d4) δ ppm: 8.19 (s, 1 H), 6.02- 6.05 (m, 1 H),
4.94- 5.00 (m, 2 H), 4.33- 4.40 (m, 1 H), 2.58- 2.68 (m, 1 H), 2.03 (s, 3 H), 1.86- 1.96 (m, 1 H),
1.56 - 1.77 (m, 2 H), 0.93 (t, J = 7.40 Hz, 3 H). MS obsd. (ESI-) [(M+H)+]: 355.0.
Example 2
3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-
2,2-dimethyl-propanoic acid
Compound 2 was prepared through following scheme:
.TFA
DIPEA
2A 2B 2
To a stirred solution of ethyl (4R)(bromomethyl)(2-chlorofluoro-phenyl)
thiazolyl-1,4-dihydropyrimidinecarboxylate (compound 2A, 0.073 g, 0.16 mmol) and 3-
[(8aS)oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid
(compound 2B, crude, 0.25 mmol) in 1,2-dichloroethane (5 mL) was added dropwise DIPEA
(0.078 mL, 0.45 mmol). The reaction mixture was stirred at room temperature until the
disappearance of compound 2A. The mixture was then diluted with EtOAc (50 mL) and washed
successively with saturated aqueous NH4Cl solution and brine. The organic layer was separated
and dried over Na2SO4. The solvent was d in vacuo and the crude t was purified by
prep-HPLC to give 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazol-
2-yl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin
yl]-2,2-dimethyl-propanoic acid (Compound 2) as a light yellow solid (12 mg). 1H NMR (400
MHz, Methanol-d4) ppm 7.92 - 8.02 (m, 1H), 7.70 - 7.80 (m, 1H), 7.21 - 7.36 (m, 2H), 7.10 -
7.21 (m, 1H), 6.19 - 6.28 (m, 1H), 3.99 - 4.14 (m, 3H), 3.81 - 3.96 (m, 3H), 3.47 - 3.56 (m, 1H),
3.38 - 3.44 (m, 1H), 3.27 - 3.32 (m, 1H), 3.15 - 3.25 (m, 1H), 3.07 - 3.14 (m, 1H), 2.79 - 2.96 (m,
2H), 2.30 - 2.41 (m, 1H), 2.13 - 2.23 (m, 1H), 1.20 (d, J = 2.76 Hz, 6H), 1.13 (m, 3H). MS:
calc’d 619 (M+H)+, measured 619 (M+H)+.
Preparation of ethyl (4R)(bromomethyl)(2-chlorofluoro-phenyl)thiazolyl-1,4-
dihydropyrimidinecarboxylate (compound 2A):
1. NaOMe, MeOH
2. NH4Cl
KOAc
HCl .
CF3CH2OH
2A-1 2A-2
2A-2a 2A-2b
CCl4
2A-2a 2A
Preparation of thiazolecarboxamidine hydrochloride und 2A-1):
To a stirred solution of thiazolecarbonitrile (1.5 g, 14 mmol) in 5 mL of dry MeOH
was added dropwise a solution of sodium methoxide (0.74 g, 14 mmol) in 10 mL of dry
methanol. The reaction mixture was stirred at room temperature until the disappearance of
starting material. Then ammonium chloride (1.5 g, 28 mmol) was added in one portion and the
reaction mixture was stirred overnight. The undissolved material was removed by tion and
the filtrate was concentrated to afford lecarboxamidine hydrochloride (compound 2A-1,
2.1 g) as a grey solid which was used directly in the next step without further purification. MS:
calc’d 128 (M+H)+, measured 128 (M+H)+.
Preparation of ethyl hlorofluoro-phenyl)methylthiazolyl-1,4-
dihydropyrimidinecarboxylate (compound 2A-2):
To a stirred solution of thiazolecarboxamidine hloride (1.3 g, 10 mmol), ethyl
cetate (1.3 g, 10 mmol) and 2-chlorofluorobenzaldehyde (1.6 g, 10 mmol) in
trifluoroethanol (30 mL) was added potassium acetate (2.0 g, 20 mmol). The reaction mixture
was refluxed for 16 hours. After it was cooled to room temperature, the reaction e was
concentrated and the residue was dissolved in ethyl acetate and then washed with brine. The
organic layer was dried over Na2SO4. The solvent was removed in vacuo and the residue was
purified by silica gel column chromatography (ethyl acetate/petroleum ether: from 1/4 to 1/2) to
afford ethyl 4-(2-chlorofluoro-phenyl)methylthiazolyl-1,4-dihydropyrimidine
carboxylate (compound 2A-2, 2.8 g) as a yellow solid. MS: calc’d (M+H)+ 380, measured
(M+H)+ 380.
Preparation of ethyl (4R)(2-chlorofluoro-phenyl)methylthiazolyl-1,4-
opyrimidinecarboxylate (compound 2A-2a):
A chiral separation of racemic compound 2A-2 eluting with a mixed t of 85%
supercritical CO2 / 15% EtOH at 100 mL/min rate on SFC (SFC-Multigram; IC: 5 × 250 mm, 5μ)
gave two enantiomers of ethyl (4R)(2-chlorofluoro-phenyl)methylthiazolyl-1,4-
dihydropyrimidinecarboxylate (compound 2A-2a, faster eluting) and ethyl (4S)(2-chloro-
3-fluoro-phenyl)methylthiazolyl-1,4-dihydropyrimidinecarboxylate (compound 2A-
2b, slower eluting). The absolute configuration of d (-)-enantiomer compound 2A-2a
([α]D20 -46.6 (c 0.28, MeOH)) was determined by X-ray diffraction study (Figure 2).
Preparation of ethyl (4R)(bromomethyl)(2-chlorofluoro-phenyl)thiazolyl-1,4-
dihydropyrimidinecarboxylate (compound 2A):
To a stirred solution of ethyl -(2-chlorofluoro-phenyl)methylthiazolyl-
1,4-dihydropyrimidinecarboxylate und 2A-2a, 0.37 g, 1.0 mmol) in CCl4 (5 mL) was
added NBS (0.20 g, 1.1 mmol) in portions. After the reaction mixture was stirred at room
temperature for 1 hour, the solvent was removed in vacuo and the residue was ed by silica
gel column chromatography to give ethyl -(bromomethyl)(2-chlorofluoro-phenyl)
thiazolyl-1,4-dihydropyrimidinecarboxylate (compound 2A, 0.35 g) as a yellow solid. MS:
calc’d 459 (M+H)+, measured 459 (M+H)+.
Preparation of 3-[(8aS)oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid (compound 2B):
.HCl
CbzCl Swern [O]
NaBH(OAc)3
2B-1 2B-2 2B-3
.TFA
Pd-C, H2 1. LiOH, H2O
Triphosgene
2. TFA, CH2Cl2
2B-4 2B-5 2B
Preparation of O1-benzyl O4-tert-butyl (2S)(hydroxymethyl)piperazine-1,4-
dicarboxylate (compound 2B-1):
To a stirred solution of tert-butyl (3S)(hydroxymethyl)piperazinecarboxylate (CAS
number: 3147417, m; for its synthesis, please refer to: Gao H., Renslo A. R. J. Org.
Chem. 2007, 72, 8591-8592) (6 g, 27.8 mmol) in saturated NaHCO3 (45 mL) and EtOAc (45 mL)
was added benzyl chloroformate (7.1 g, 41.7 mmol) dropwise at 0oC. Then the reaction mixture
was stirred at room temperature for 15 hours. The reaction mixture was diluted with EtOAc (60
mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (35 mL).
The combined organic layers were dried over Na2SO4. The t was removed in vacuo to give
the crude product, which was purified by silica gel column chromatography (Petroleum ether :
EtOAc = 10:1 to 1:1) to give O1-benzyl O4-tert-butyl (2S)(hydroxymethyl)piperazine-1,4-
dicarboxylate (compound 2B-1, 6.7 g). MS: calc’d 351 (M+H)+, measured 351 (M+H)+.
Preparation of O1-benzyl O4-tert-butyl (2S)formylpiperazine-1,4-dicarboxylate
(compound 2B-2):
To a stirred solution of oxalyl chloride (3.64 g, 28.6 mmol) in anhydrous
dichloromethane (80 mL) at -78 oC was added se dimethyl sulfoxide (4.47 g, 57.3 mmol).
After 10 minutes, a solution of O1-benzyl O4-tert-butyl (2S)(hydroxymethyl)piperazine-1,4-
dicarboxylate (compound 2B-1, 6.7 g, 19.1 mmol) in dichloromethane (20 mL) was added
se. After the mixture was d for 30 minutes at -78 oC, N,N-diisopropylethylamine
(14.78 g, 114.6 mmol) was added and the reaction e was stirred for 30 minutes. After the
reaction mixture was slowly warmed to 0 oC over 30 minutes, it was d with
dichloromethane (80 mL), washed with 5% aqueous citric acid (10 mL), brine and then dried
over Na2SO4. After filtration, the e was concentrated in vacuo to get the crude product O1-
benzyl O4-tert-butyl (2S)formylpiperazine-1,4-dicarboxylate (compound 2B-2, 7.0 g). MS:
calc’d 349 (M+H)+, measured 349 (M+H)+.
Preparation of O1-benzyl t-butyl (2R)[[(3-ethoxy-2,2-dimethyloxopropyl
)amino]methyl]piperazine-1,4-dicarboxylate (compound 2B-3):
To a stirred solution of ethyl 3-amino-2,2-dimethyl-propanoate hydrochloride salt (3.4 g,
18.6 mmol) in anhydrous DCM (100 mL) was added DIPEA (2.6 g, 27.3 mmol) at room
temperature. Then O1-benzyl O4-tert-butyl (2S)formylpiperazine-1,4-dicarboxylate
(compound 2B-2, crude, 7.0 g, 20 mmol) was added, followed by NaBH(OAc)3 (6.3 g, 29.8
mmol) and AcOH (1.5 mL) at 0 oC. The reaction mixture was d for 16 hours at room
temperature. Water (100 mL) was added and the mixture was extracted with DCM (100 mL).
The organic layer was dried and concentrated in vacuo to give crude product of O1-benzyl O4-
tert-butyl (2R)[[(3-ethoxy-2,2-dimethyloxo-propyl)amino]methyl]piperazine-1,4-
dicarboxylate und 2B-3, 7.3 g). MS: calc’d 478 (M+H)+, measured 478 (M+H)+.
Preparation of tert-butyl (3R)[[(3-ethoxy-2,2-dimethyloxopropyl
)amino]methyl]piperazinecarboxylate (compound 2B-4):
To a solution of O1-benzyl O4-tert-butyl (2R)[[(3-ethoxy-2,2-dimethyloxopropyl
)amino]methyl]piperazine-1,4-dicarboxylate und 2B-3, crude, 3.3 g, 6.9 mmol) in
EtOH (100 mL) was added 10% palladium on carbon (1 g). Then the mixture was stirred at 50
oC for 3 hours under hydrogen atmosphere (50 Psi). The reaction mixture was filtered and the
filtrate was concentrated in vacuo to get the tert-butyl (3R)[[(3-ethoxy-2,2-dimethyloxopropyl
)amino]methyl]piperazinecarboxylate (compound 2B-4, 1.8 g). MS: calc’d 344 (M+H)+,
measured 344 (M+H)+.
Preparation of tert-butyl (8aR)(3-ethoxy-2,2-dimethyloxo-propyl)oxo-5,6,8,8atetrahydro-1H-imidazo
[1,5-a]pyrazinecarboxylate und 2B-5):
To a solution of tert-butyl (3R)[[(3-ethoxy-2,2-dimethyloxopropyl
]methyl]piperazinecarboxylate (compound 2B-4, 1.8 g, 5.2 mmol) in anhydrous
dichloromethane (60 mL) was added N,N-diisopropylethylamine (3.4 g, 26.2 mmol) at 0 oC.
Then triphosgene (783 mg, 2.6 mmol) was added at 0 oC and the mixture was stirred at 10-15 oC
for 16 hours. Water (50 mL) was added and the mixture was extracted with dichloromethane (60
mL). The organic layer was dried over Na2SO4 and the solvent was removed in vacuo to give the
crude product. The crude product was purified by silica gel column tography (Petroleum
ether: EtOAc = 5:1 to 1:1) to give tert-butyl (8aR)(3-ethoxy-2,2-dimethyloxo-propyl)
oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinecarboxylate (compound 2B-5, 1.3 g). MS:
calc’d 370 (M+H)+, ed 370 (M+H)+.
Preparation of 3-[(8aS)oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl]-2,2-
dimethyl-propanoic acid und 2B):
To a stirred solution of tert-butyl 2-(3-ethoxy-2,2-dimethyloxo-propyl)oxo-
,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinecarboxylate und 2B-5, 94 mg, 0.25
mmol) in THF (3 mL) was added a solution of LiOH∙H2O (84 mg, 2.0 mmol) in H2O (1 mL) at
room temperature. After the reaction mixture was stirred at room temperature overnight, it was
acidified to PH 3~4 with 1N HCl at 0 oC. The mixture was then trated in vacuo and
azeotropically dried with toluene to give the crude acid which was dissolved in dichloromethane
(2 mL) and treated with trifluoroacetic acid (2 mL) at room temperature. After the reaction
mixture was stirred at room temperature for 1 hour, the solvent was removed in vacuo to give 3-
[(8aS)oxo-1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid
(compound 2B) which was used directly. MS: calc’d 242 (M+H)+, measured 242 (M+H)+.
[(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanyl]-
cyclopropyl-methyl] acetate (Compound 3)
3
Compound 3 was prepared through following scheme:
Ac O
2 L-(-)-menthol
3A 3B 3C trans
MMTrCl
3E 3F
Ac O
NaBH
3G 3H 3I
3 3J
Preparation of 5-hydroxy-1,3-oxathiolanecarboxylic acid
To a stirred solution of 1,4-dithiane-2,5-diol (compound 3A, 150 g, 0.98 mol) in methyl
tert-butyl ether (500 mL) and cyclohexane (150 mL) was added glyoxylic acid (180 g, 1.96 mol).
The resulting reaction mixture was stirred at 80 oC under Dean-Stark conditions for 16 hours.
The resulting solution was concentrated in vacuo. The residue was purified by column
chromatography on silica gel (eluting with 1:7 ethyl acetate in petroleum ether to 100% ethyl
acetate) to afford 220 g of the crude 5-hydroxy-1,3-oxathiolanecarboxylic acid (compound
3B), which was used directly in the next step without further cation.
Preparation of transacetoxy-1,3-oxathiolanecarboxylic acid
3C trans
To a solution of 5-hydroxy-1,3-oxathiolanecarboxylic acid (compound 3B, 220 g, 1.5
mol) in HOAc (1.5 L) was added concentrated sulfuric acid (1 mL) and acetic anhydride (50 g,
0.5 mol). After being stirred at room ature for 16 hours, the resulting on mixture was
diluted with water and extracted with EtOAc. The c phase was combined and concentrated
in vacuo. The e was ed by column chromatography on silica gel (eluting with 1:10 to
1:7 ethyl acetate in petroleum ether) to afford crude product, which was recrystallized from
toluene to give 10 g of transacetoxy-1,3-oxathiolanecarboxylic acid (compound 3C trans).
(For the synthesis, please also refer to: J. Org. Chem. 1995, 60, 2621-2623.)
Compound 3C trans: 1H NMR (400 MHz, 6) δ ppm: 13.26 (br, 1 H), 6.66 (d, J =
4.0 Hz, 1 H), 5.66 (s, 1 H), 3.30 - 3.37 (m, 1 H), 3.19 - 3.25 (m, 1 H), 2.04 (s, 3 H).
Preparation of [(1R,2S,5R)isopropylmethyl-cyclohexyl] (2S,5S)acetoxy-1,3-
oxathiolanecarboxylate
A solution of dicyclohexylcarbodiimide (12 g, 57 mmol) in DCM (50 mL) was added to a
round bottom flask containing a solution of transacetoxy-1,3-oxathiolanecarboxylic acid
(compound 3C trans, 10 g, 52 mmol), L-(-)-menthol (8.9 g, 57 mmol) and DMAP (0.6 g, 5.2
mmol) in DCM (100 mL) at 0 oC. After the reaction mixture was stirred at room ature
for 16 hours, methanol (2 mL) and glacial acetic acid (2 mL) were added. The reaction mixture
was stirred for another 10 minutes and then diluted with hexane (250 mL), filtrated through
celite and the filtrate was concentrated to yield crude product. (J. Org. Chem. 1995, 60, 2621-
2623). The crude product was re-dissolved in hexane (250 mL), ed and the filtrate was
concentrated in vacuo. The residue was purified by ritical fluid chromatography (SFC) to
give 3.2 g of [(1R,2S,5R)isopropylmethyl-cyclohexyl] (2S,5S)acetoxy-1,3-oxathiolane-
2-carboxylate (compound 3D) with a diastereoisomeric excess of 85% as a colorless oil. The
diastereoisomeric excess value of compound 3D was obtained by HPLC (Agilent 1260 HPLC)
analysis using a chiral column (CHIRALPAK IA-3 ODH (4.6 mm × 250 mm, 5 μm)). The
mobile phase of the chiral analysis was 20:80 acetonitrile in MeOH.
Compound 3D: 1H NMR (400 MHz, CDCl3) δ ppm: 6.81 (d, J = 4.0 Hz, 1 H), 5.63 (s, 1
H), 4.76 (dt, J = 10.9, 4.5 Hz, 1 H), 3.44 (dd, J = 11.7, 4.1 Hz, 1 H), 3.17 (d, J = 11.8 Hz, 1 H),
2.11 (s, 3 H), 2.00 (d, J = 12.0 Hz, 1 H), 1.85 (dt, J = 6.9, 2.5 Hz, 1 H), 1.69 (d, J = 11.0 Hz, 2
H), 1.55 - 1.26 (m, 3 H), 1.11 - 1.00 (m, 2 H), 0.91 (dd, J = 6.8, 9.8 Hz, 6 H), 0.76 (d, J = 7.0
Hz, 3 H).
Preparation of [(1R,2S,5R)isopropylmethyl-cyclohexyl] (2S,5R)(5-aminooxothiazolo
[4,5-d]pyrimidinyl)-1,3-oxathiolanecarboxylate
3E
A sion of 5-amino-3H-thiazolo[4,5-d]pyrimidinone (6.0 g, 36 mmol) and BSA
(24.0 g, 118 mmol) in DCE (250 mL) was heated at 85 oC for 1 hour. The on mixture was
cooled to 0 oC, to the above mixture was added a on of [(1R,2S,5R)isopropylmethylcyclohexyl
] (2S,5S)acetoxy-1,3-oxathiolanecarboxylate (compound 3D, 9.0 g, 27 mmol) in
DCE (10 mL), followed by TMSI (14 g, 70 mmol) dropwise. The reaction mixture was stirred at
60 oC for 5 hours, quenched by aqueous NaHCO3 solution, and then extracted with EtOAc. The
organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated to give the
crude product as an oil, which was purified by column chromatography on silica gel (eluting
with 1:100 to 1:50 methanol in dichloromethane) to give 7.7 g of a mixture of two isomers,
which was further purified and separated by preparative HPLC to give the d 2.8 g of beta
isomer [(1R,2S,5R)isopropylmethyl-cyclohexyl] (2S,5R)(5-aminooxo-thiazolo[4,5-
d]pyrimidinyl)-1,3-oxathiolanecarboxylate (compound 3E) as a white solid. The
configuration of compound 3E was determined by NOESY.
Compound 3E: 1H NMR (400 MHz, CDCl3) δ ppm: 8.17 (s, 1 H), 6.44 (m, 1 H), 5.51 (s,
1 H), 5.12 (bs, 2 H), 4.78 (m, 1 H), 4.47 (m, 1 H), 3.16 (m, 1 H), 2.00 (m, 1 H), 1.79 (m, 1 H),
1.62 (m, 2 H), 1.38 (m, 2 H), 0.98 (m, 2 H), 0.9 - 0.72 (m, 10 H). MS obsd. (ESI+) [(M+H)+]:
439.
Preparation of (2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-N-methoxy-N-
methyl-1,3-oxathiolanecarboxamide
A solution of [(1R,2S,5R)isopropylmethyl-cyclohexyl] (2S,5R)(5-aminooxo-
thiazolo[4,5-d]pyrimidinyl)-1,3-oxathiolanecarboxylate (compound 3E, 3.0 g, 7.5 mmol)
in 80% TFA aqueous (20 mL) was stirred at 50 oC for 16 hours, and then concentrated to give
the crude acid as a white solid, which was re-dissolved in THF (40 mL). To the above mixture
was added N-methoxymethylamine hydrochloride (2.1 g, 22 mmol), DIPEA (14.5 g, 112 mmol)
and HATU (8.36 g, 22 mol) at room temperature. After being d at room temperature for 16
hours, the reaction mixture was d with DCM, washed by water and brine, dried over
anhydrous Na2SO4, and concentrated to give the crude t which was purified by flash
tography on silica gel (eluting with 1:100 to 1:50 methanol in dichloromethane) to give
2.1 g of (2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-N-methoxy-N-methyl-1,3-
oxathiolanecarboxamide (compound 3F) as a white solid.
Compound 3F: 1H NMR (400 MHz, CDCl3) δ ppm: 8.16 (s, 1 H), 6.42 (m, 1 H), 5.83 (s, 1
H), 5.14 (bs, 2 H), 4.46 (t, J = 9.6 Hz, 1 H), 3.72 (s, 3 H), 3.23 (s, 3 H), 3.15 (m ,1 H). MS obsd.
(ESI+) [(M+H)+]: 344.
Preparation of (2S,5R)-N-methoxy[5-[[(4-methoxyphenyl)-diphenyl-methyl]amino]
iazolo[4,5-d]pyrimidinyl]-N-methyl-1,3-oxathiolanecarboxamide
To a solution of )(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-N-methoxy-N-
methyl-1,3-oxathiolanecarboxamide (compound 3F, 2.1 g, 6.1 mmol) in DCM (30 mL) was
added collidine (1.45 g, 12 mmol), AgNO3 (2.04 g, 12 mmol) and MMTrCl (3.8 g, 12 mmol) at
room temperature. After being stirred at room temperature for 16 hours, the reaction mixture was
diluted with DCM, filtered to remove the solid. The filtrate was washed with water and brine,
dried over ous Na2SO4 and concentrated to give the crude product, which was purified by
flash tography on silica gel (eluting with 1:100 to 2:1 ethyl acetate in petroleum ether) to
give 3.6 g of (2S,5R)-N-methoxy[5-[[(4-methoxyphenyl)-diphenyl-methyl]amino]oxothiazolo
[4,5-d]pyrimidinyl]-N-methyl-1,3-oxathiolanecarboxamide (compound 3G) as a
yellow solid. (ESI+) [(M+H)+]: 616.
Preparation of 3-[(2S,5R)[cyclopropyl(hydroxy)methyl]-1,3-oxathiolanyl][[(4-
methoxyphenyl)-diphenyl-methyl]amino]thiazolo[4,5-d]pyrimidinone
To a solution of (2S,5R)-N-methoxy[5-[[(4-methoxyphenyl)-diphenyl-methyl]amino]
oxo-thiazolo[4,5-d]pyrimidinyl]-N-methyl-1,3-oxathiolanecarboxamide (compound 3G, 3
g, 5 mmol) in THF (40 mL) was added Grignard reagent, cyclopropylmagnesium bromide (0.5
M, 25 mL) at 0 oC. The reaction mixture was stirred at 0 oC for 30 min. The reaction was
quenched with saturated NH4Cl solution and extracted with EtOAc. The organic layer was dried
and concentrated to give the crude product, which was re-dissolved in MeOH (50 mL). To the
above mixture was added NaBH4 (2.0 g, 540 mmol) at 0 oC. The reaction mixture was d at
room temperature for 30 min. The reaction was ed with saturated NH4Cl solution and
extracted with DCM. The organic layer was dried over anhydrous Na2SO4 and concentrated to
give the crude product, which was purified by flash chromatography on silica gel ng with
1:100 to 1:1 ethyl acetate in petroleum ether) to give 1.8 g of 3-[(2S,5R)
[cyclopropyl(hydroxy)methyl]-1,3-oxathiolanyl][[(4-methoxyphenyl)-diphenylmethyl
]amino]thiazolo[4,5-d]pyrimidinone (compound 3H) as a yellow solid. (ESI+)
[(M+H)+]: 599.
Preparation of [cyclopropyl-[(2S,5R)[5-[[(4-methoxyphenyl)-diphenyl-methyl]amino]
oxo-thiazolo[4,5-d]pyrimidinyl]-1,3-oxathiolanyl]methyl] acetate
To a solution of 3-[(2S,5R)[cyclopropyl(hydroxy)methyl]-1,3-oxathiolanyl][[(4-
methoxy phenyl)-diphenyl-methyl]amino]thiazolo[4,5-d]pyrimidinone (compound 3H, 1.2 g,
2 mmol) in DCM (10 mL) was added TEA (800 mg, 8 mmol), DMAP (30 mg, 0.2 mmol) and
Ac2O (400 mg, 4 mmol) at 0 oC. The reaction mixture was stirred at room temperature for 48
hours. After the reaction was completed, the reaction was quenched by water, extracted with
DCM. The organic layer was dried and concentrated to give 1.3 g of the crude product
propyl-[(2S,5R)[5-[[(4-methoxyphenyl)-diphenyl-methyl]amino]oxo-thiazolo[4,5-
d]pyrimidinyl]-1,3-oxathiolanyl]methyl] acetate (compound 3I) as a white solid, which
was used directly in the next step without further purification. (ESI+) +]: 641.
Preparation of [(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-
oxathiolanyl]-cyclopropyl-methyl] acetate
A solution of [cyclopropyl-[(2S,5R)[5-[[(4-methoxyphenyl)-diphenyl-methyl]amino]
oxo-thiazolo[4,5-d]pyrimidinyl]-1,3-oxathiolanyl]methyl] acetate und 3I, 1.3 g, 2
mmol) in 90% HCOOH aqueous solution (25 mL) was d at room temperature for 1 hour.
The reaction mixture was concentrated and the residue was r purified and separated by
preparative HPLC to give 114 mg of [(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidin-
3-yl)-1,3-oxathiolanyl]-cyclopropyl-methyl] acetate (compound 3) as a white solid.
Compound 3: 1H NMR (400 MHz, Methanol-d4) δ ppm: 8.20 (s, 1 H), 6.34 (m, 1 H), 5.34
(d, J = 6.4 Hz, 1 H), 4.54 (t, J = 6.0 Hz, 1 H), 4.18 (t, J = 8.4 Hz, 1 H), 3.31 (t, J = 6.0 Hz, 1 H),
2.02 (s, 3 H), 1.13 (m ,1 H), 0.65 - 0.42 (m, 4 H). MS obsd. (ESI+) [(M+Na)+]: 391.
Preparation of 5-amino[(2S,5R)[(S)-cyclopropyl(hydroxy)methyl]-1,3-oxathiolan
yl]thiazolo[4,5-d]pyrimidinone
To a solution of [(S)-[(2S,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)-1,3-
oxathiolanyl]-cyclopropyl-methyl] acetate (compound 3, 500 mg, 1.36 mmol) in methanol (5
mL) was added K2CO3 (94 mg, 0.68 mmol). After being stirred at room temperature for 4 hours,
the reaction was quenched with HOAc to pH 7 and then concentrated in vacuo. The residue was
diluted with EtOAc and filtered. The filtrate was concentrated in vacuo. The e was purified
and separated by preparative HPLC to give 45 mg of 5-amino[(2S,5R)[(S)-
cyclopropyl(hydroxy)methyl]-1,3-oxathiolanyl]thiazolo[4,5-d]pyrimidinone und 3J)
as a white powder.
Compound 3J: The absolute structure was determined by 1H NMR and single crystal X-
ray structural analysis as shown in Figure 3. 1H NMR (400 MHz, Methanol-d4) δ ppm: 8.25 (s, 1
H), 6.39 (dd, J = 9.16, 5.65 Hz, 1 H), 5.24 (d, J = 5.27 Hz, 1 H), 4.06 (dd, J = 10.29, 9.29 Hz, 1
H), 3.13 - 3.30 (m, 2 H), 0.37 - 1.04 (m, 5 H). MS obsd. (ESI+) [(M+H)+]: 327.0.
Example 4
3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-
2,2-dimethyl-propanoic acid (Compound 4)
3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4-
dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-
methyl-propanoic acid (Compound 4)
nd 4 was prepared through following scheme:
.TFA
DIPEA
4A 2B 4
The title compound was prepared in y to Compound 2 by using ethyl (4S)
(bromomethyl)(3-fluoromethyl-phenyl)thiazolyl-1,4-dihydropyrimidine
carboxylate (compound 4A) instead of ethyl (4R)(bromomethyl)(2-chlorofluorophenyl
)thiazolyl-1,4-dihydropyrimidinecarboxylate (compound 2A). Compound 4 was
obtained as a light yellow solid (132 mg). 1H NMR (400 MHz, Methanol-d4) δ ppm 7.95 (d, J =
3.3 Hz, 1H), 7.75 (d, J = 3.3 Hz, 1H), 7.08-7.23 (m, 2H), 6.95 (t, J = 8.8 Hz, 1H), 5.99 (s, 1H),
4.02-4.17 (m, 3H), .00 (m, 3H), 3.36-3.57 (m, 2H), 3.26-3.33 (m, 1H), 3.17-3.25 (m, 1H),
3.11 (dd, J = 9.3, 4.0 Hz, 1H), 2.78-2.99 (m, 2H), 2.53 (d, J = 2.0 Hz, 3H), 2.39 (dd, J = 11.2, 8.2
Hz, 1H), 2.14-2.26 (m, 1H), 1.21 (d, J = 2.8 Hz, 6H), 1.15 ppm (t, J = 7.2 Hz, 3H). MS: calc’d
599 (M+H)+, measured 599 (M+H)+.
Preparation of ethyl (4S)(bromomethyl)(3-fluoromethyl-phenyl)thiazol-
,4-dihydropyrimidinecarboxylate (compound 4A):
Compound 4A was prepared in analogy to compound 2A by using 2-methyl
fluorobenzaldehyde instead of 2-chlorofluorobenzaldehyde. The optical on of compound
4A: [α]D20 -21.0 (c 0.10, MeOH).
Example 5
-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H-
thiazolo[4,5-d]pyrimidine-2,7-dione (compound 11)
Compound 11
Compound 11 was prepared according to the following Scheme.
1H 11A 11
Preparation of [(2R,3R,5S)[(1S)acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-
d]pyrimidinyl)tetrahydrofuranyl] acetate
To a suspension of 5-amino-3,6-dihydrothiazolo[4,5-d]pyrimidine-2,7-dione (5.37 g, 29.1
mmol) and [(3R,5S)acetoxy[(1S)acetoxypropyl]tetrahydrofuranyl] acetate (compound
1H, 2.8 g, 9.7 mmol) in itrile (140 mL) was added BSA (21.4 mL, 87.3 mmol). The
reaction mixture was stirred at 65 oC for 1.5 hour under argon to form a clear solution. Then to
the solution was added TMSOTf (9.8 g, 43.7 mmol) and the e was stirred at 65 oC for
another 3 hours. The reaction was concentrated in vacuum. The residue was dissolved in EtOAc
(200 mL) and extracted with saturated NaHCO3 solution (50 mL). A precipitate was out of the
organic layer. The resulting mixture was filtered and the filtrate was washed with brine (50 mL),
dried over Na2SO4 and concentrated in vacuum to give 2.3 g of the crude product [(2R,3R,5S)
1-acetoxypropyl](5-amino-2,7-dioxo-6H-thiazolo[4,5-d]pyrimidinyl)tetrahydrofuran-
3-yl] acetate (compound 11A) as a yellow solid. MS obsd. (ESI-) [(M+H)+]: 413.1.
Preparation of 5-amino[(2R,3R,5S)hydroxy[(1S)
hydroxypropyl]tetrahydrofuranyl]-6H-thiazolo[4,5-d]pyrimidine-2,7-dione
To a solution of [(2R,3R,5S)[(1S)acetoxypropyl](5-amino-2,7-dioxo-6H-
lo[4,5-d]pyrimidinyl)tetrahydrofuranyl] acetate (compound 11A, 2.3 g, 5.58 mmol)
in methanol (100 mL) was added sodium methoxide (1.5 g, 27.9 mmol) After the on, the
mixture was stirred at room temperature for 1.5 hours (monitored by TLC). After the reaction
was ted, the reaction was quenched with saturated aqueous NH4Cl (50 mL). The resulting
mixture was concentrated in vacum to remove most of MeOH. The residue was extracted with
EtOAc (100 mL) ten times. The combined c layer was washed with brine (100 ml), dried
over Na2SO4 and concentrated in vacuum. The residue was purified by silica gel column eluted
with OH=20/1 to 10/1 to give 360 mg of 5-amino[(2R,3R,5S)hydroxy[(1S)
hydroxypropyl]tetrahydrofuranyl]-6H-thiazolo[4,5-d]pyrimidine-2,7-dione (Compound 11) as
a white solid and 550 mg of crude product..
nd 11: 1H NMR (400 MHz, DMSO-d6) δ 11.22 (br s, 1H), 6.95 (br s, 2H), 5.72 (d,
J=2.26 Hz, 1H), 5.42 (d, J=4.52 Hz, 1H), 4.73 (m, 1H), 4.53 (d, J=6.02 Hz, 1H), 3.96 (m, 1H),
3.25-3.32 (m, 1H), 2.25-2.48 (m, 1H), 1.66-1.74 (m, 1H), 1.35-1.46 (m, 1H), 1.19-1.31 (m, 1H),
0.88 (t, J=7.28 Hz, 3H)
Example 6
HEK293-Blue-hTLR-7 cells assay:
A stable HEK293-Blue-hTLR-7 cell line was purchased from InvivoGen : hkb-htlr7,
San Diego, California, USA). These cells were designed for studying the stimulation of human
TLR7 by monitoring the activation of NF-κB. A SEAP ted embryonic ne phosphatase)
reporter gene was placed under the control of the IFN-βminimal promoter fused to five NF-κB
and APbinding sites. The SEAP was induced by activating NF-κB and AP-1 via stimulating
HEK-Blue hTLR7 cells with TLR7 ligands. Therefore the reporter expression was regulated by
the NF-κB promoter upon stimulation of human TLR7 for 20 hours. The cell culture supernatant
SEAP reporter ty was determined using QUANTI-Blue™ kit (Cat.#: rep-qb1, Invivogen,
San Diego, Ca, USA) at a wavelength of 640 nm, a detection medium that turns purple or blue in
the presence of alkaline phosphatase.
HEK293-Blue-hTLR7 cells were incubated at a density of 250,000~450,000 cells/mL in a
volume of 180 µL in a l plate in Dulbecco's Modified Eagle's medium (DMEM)
containing 4.5 g/L glucose, 50 U/mL penicillin, 50 mg/mL streptomycin, 100 mg/mL Normocin,
2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum for 24 h. Then the HEK293-
Blue-hTLR-7 cells were incubated with addition of 20 μL test compound in a serial dilution in
the presence of final DMSO at 1% and perform tion under 37 ºC in a CO2 incubator for 20
hours. Then 20 µL of the atant from each well was incubated with 180 µL Quanti-blue
substrate solution at 37°C for 2 hours and the absorbance was read at 620~655 nm using a
spectrophotometer. The signalling pathway that TLR7 activation leads to downstream NF-κB
tion has been widely accepted, and therefore similar reporter assay was also widely used
for evaluating TLR7 agonist (Tsuneyasu Kaisho and Takashi Tanaka, Trends in Immunology,
Volume 29, Issue 7, July 2008, Pages 329.sci; Hiroaki Hemmi et al, Nature Immunology 3, 196 -
200 (2002).
The TLR7 agonism activity in HEK293- hTLR-7 assay of compound 11 was 72µM.
Example 6
A combination of TLR7 t (Compound 1) and HBV capsid assembly inhibitor
(Compound 2) potently reduced HBV DNA and HBsAg in AAV-HBV mouse model
Animal model
4-week old male C57BL/6 mice, specific pathogen free, were purchased from Shanghai
tory Animal Center of Chinese Academy of Sciences (SLAC) and housed in an animal
care facility in dually ventilated cages under controlled temperature and light conditions
following the Institutional Animal Care ines. AAV/HBV virus was purchased from
Beijing FivePlus Molecular Medicine Institute (Beijing, China). This recombinant virus carries
1.3 copies of the HBV genome, which was packaged in AAV serotype 8 (AAV8) capsids.
C57BL/6 mice were injected with 200µL of recombinant virus, diluted in saline buffer, through
tail vein ion. The mice were bled at days 7 and 14 post injection to r HBV surface
antigen ), HBV e antigen (HBeAg), HBs dy (HBsAb) and HBV genomic DNA in
serum, and then were randomly grouped ing to these HBV biomarkers.
Measurement of HBV biomarkers
Serum HBsAg and HBeAg was measured using CLIA kits (Autobio Diagnostics Co., Ltd ,
Zhengzhou, China) according to the manufacturer’s instructions. The lower limit of detection for
HBsAg and HBeAg was 0.1ng/mL and U/mL (national clinical unit/mL) respectively.
Serum dilution of 100-fold (for HBsAg) or 500-fold (for HBeAg) was used to obtain values
within the linear range of the standard curve. Serum HBV DNA was extracted using a MagNA
Pure 96 DNA and Viral NA Small Volume Kit (Roche) following the manufacturer’s
instructions. The DNA samples were analyzed by real-time quantitative PCR (qPCR) using a
HBV-specific primer and probe set for specific amplification and detection of a 128bp HBV
genome region from the nucleotide 2969 to 3096. The ces of the primers and probe are
shown as follows:
Forward primer: AAGAAAAACCCCGCCTGTAA;
Reverse primer: CCTGTTCTGACTACTGCCTCTCC;
HBV-Probe: 5'TARMA-CCTGATGTGATGTTCTCCATGTTCAGC-BHQ2-3'.
Anti-HBs in the serum was measured on day 24 after the treatment ended using Anti-HBs
CLIA kits (Autobio Diagnostics Co., Ltd , Zhengzhou, China) following the manufacturer’s
instructions. The serum samples were 3-fold diluted and 50 μL of the diluted samples were used
for the assay.
Experiment design and results
10mg/mL of Compound 1 and mL of Compound 2 was ated as an inclusion
complex with 2% Klucel LF, 0.1% rbate 80, and 0.1% Parabens in water. All the mice
were orally dosed for a total of 6 weeks followed by a 2-week off-treatment period. In one
single-treatment control study, the five mice of the group Compound 1 were treated with
Compound 1 at 100mg/kg every other day (QOD). The vehicle group was treated with an
equivalent volume of oral-QD vehicle placebo (2% Klucel LF, 0.1% Polysorbate 80, and 0.1%
Parabens in water). In the combination therapy study, the five mice of the group Compound 2
were administered at 12mg/kg orally once daily (QD). The group Combo received 100mg/kg of
nd 1 QOD plus 12mg/kg Compound 2 QD. The vehicle group was treated with an
equivalent volume of oral-QD vehicle placebo (2% Klucel LF, 0.1% Polysorbate 80, and 0.1%
Parabens in water).
A mouse model with high level expression of both HBV DNA and HBsAg was generated
by injecting C57BL/6 mice with a recombinant adeno-associated virus (AAV) ng a
replicable HBV genome (AAV-HBV). At 3 weeks post infection, persistent HBV viral markers
such as HBV genomic DNA, HBsAg, and HBeAg were detected in the sera of the infected mice.
With the long-lasting HBV viremia and a fully ent immune , the AAV-HBV
model was used to investigate the individual and combined effect of Compound 1, a prodrug of
a TLR7 agonist, the active form of which, after sion, induces potent innate immune
responses, and Compound 2, a small molecule which inhibits HBV capsid assembly. As shown
in Figure 1, after a 6-week ent, Compound 1 induced more than 2-log reduction in HBV
DNA and more than 1-log reduction in HBsAg. Compound 2 alone reduced HBV DNA by
more than 3-log and to the level below the LLQ (lower limit of quantification), and moderately
reduced the HBsAg level. The combination of the Compound 1 and Compound 2 ed in a
nable reduction in both HBV DNA and HBsAg to the level below the LLQ even at the end
of a 2-week off-treatment period. The results provide evidence for the synergistic antiviral effect
of the novel y with the combination treatment of a TLR7 agonist and a HBV capsid
assembly inhibitor.
Example 7
A combination of TLR7 agonist (Compound 1 and 3) and HBV capsid assembly
inhibitor (Compound 4 and 5) potently reduced HBV DNA and HBsAg in AAV-HBV
mouse model
In another independent study, more combinations of a TLR7 agonist plus a Capsid
inhibitor and corresponding single compound treatments were tested (summarized in Table 2)
using the same AAV-HBV mouse model and method of measurement of HBV biomarkers
described in Example 5.
Table 2. Combination study design in AAV-HBV mouse model for Compound 1, 3, 4 and 5
Treatment
Group # Mice#
Compound Dose (mg/kg) Drug delivery
1 8 vehicle 0
PO, QOD, 42D
2 8 Compound 1 100
3 8 Compound 4 20 PO, QD, 42D
4 8 Compound 3 30 PO, QOD, 42D
8 Compound 5 12 PO, QD, 42D
Compound 1 100 PO, QOD, 42D
6 8
Compound 4 20 PO, QD, 42D
nd 3 30 PO, QOD, 42D
7 8
nd 4 20 PO, QD, 42D
Compound 1 100 PO, QOD, 42D
8 8
Compound 5 12 PO, QD, 42D
In this study, eight mice were recruited in each group, and animals ed the first dose
on day 28 post AAV-HBV infection. The tested combinations included Compound 1 plus
Compound 4, Compound 3 plus Compound 4, and Compound 1 plus Compound 5. All
compounds were formulated as an inclusion complex with 2% Klucel LF, 0.1% rbate 80,
and 0.1% Parabens in water, and an equivalent volume of placebo containing 2% Klucel LF,
0.1% rbate 80, and 0.1% Parabens was used in the vehicle group. Specifically, for the
combination of Compound 1 plus Compound 4, 10mg/mL of Compound 1 and 2mg/mL of
nd 4 was ated. The group Compound 1 was orally dosed at 100mg/kg QOD,
while the group Compound 4 were orally dosed at 20mg/kg QD. The corresponding Combo
group received 100mg/kg of Compound 1 QOD plus 20mg/kg nd 4 QD. For the
combination of Compound 3 plus Compound 4, 3mg/mL of Compound 3 and 2mg/mL of
Compound 4 was formulated. The group Compound 3 were orally dosed at 30mg/kg QOD,
while the group Compound 4 were orally dosed at 20mg/kg QD. The corresponding Combo
group received 30mg/kg of Compound 3 QOD plus 20mg/kg Compound 4 QD. For the
combination of nd 1 plus Compound 5, 10mg/mL of Compound 1 and 1.2mg/mL of
Compound 5 was formulated. The group Compound 1 were orally dosed at 100mg/kg QOD,
while the group Compound 5 were orally dosed at 12mg/kg QD. The corresponding Combo
group received 100mg/kg of Compound 1 QOD plus 12mg/kg nd 5 QD. After the first
dose, mice were submandibularly bled (75 μL blood/mouse) twice per week for serum collection
until the end of the studies. The collected blood were left at 37°C for at least 30 minutes to
coagulate and then centrifuged at 13,200 × g, 4°C for 3 minutes to obtain mouse serum. These
serum samples were subjected to analysis of HBV biomarkers.
As shown in Figure 4, single treatment of Compound 4 at 20mg/kg inhibited HBV DNA
and reduced HBsAg by 2-log at the end of 6-week treatment. The combination of Compound 1
(TLR7 agonist) plus Compound 4 (HBV capsid inhibitor) clearly demonstrated a superior
antiviral effect ally in controlling the HBsAg. In all animals taking the ation
therapy, their HBsAg d to the level close to or below the LLQ within 4 weeks of the
treatment, and a more than 3.5-log HBsAg ion at the end of the treatment could last for at
least 6 weeks during the off-treatment period. During the off-treatment period, 6 out of 8 mice
were found to have developed detectable levels of anti-HBs, as shown in Figure 7.
As shown in Figure 5, another TLR7 agonist Compound 3 also reduced both HBV DNA
and HBsAg. The combination of Compound 3 plus the capsid inhibitor Compound 4 exhibited
further reduction in HBV DNA (>4 log) and in HBsAg (2.7-log). As shown in Figure 7, 3 out
of 8 mice taking Compound 3 plus Compound 4 ped detectable levels of anti-HBs
during the 6-week off-treatment period.
As shown in Figure 6, Compound 5 is another capsid inhibitor which reduced both HBV
DNA and HBsAg. The ation of Compound 5 plus the TLR7 agonist Compound 1
further suppressed HBsAg below the LLQ within 4 weeks post ent, and the viral
reduction was ned throughout the study even after the treatment was removed for 6 weeks.
As shown in Figure 7, 4 out of 8 mice taking Compound 1 plus nd 5 developed
detectable levels of anti-HBs during the 6-week off-treatment period.
Example 8
A combination of TLR7 agonist (Compound 1 and 8) and HBV capsid assembly inhibitor
(Compound 4 and 10) potently reduced HBV DNA and HBsAg in V mouse model
In another independent study, more combinations of a TLR7 agonist plus a Capsid
inhibitor and ponding single nd treatments were tested (as summarized in Table 3)
using the same AAV-HBV mouse model and methods of measurement of HBV kers
described in Example 5.
Table 3. Combination study design in AAV-HBV mouse model for Compound 1, 4, 8 and 10
Treatment and regimen
Group # Mice#
Compound Dose (mg/kg) Drug delivery
1 7 vehicle 0
2 7 Compound 1 100 PO, QOD, 42D,
3 7 Compound 8 300
4 7 Compound 4 20
PO, QD, 42D
7 Compound 10 20
Compound 1 100 PO, QOD, 42D
6 7
Compound 10 20 PO, QD, 42D
Compound 8 300 PO, QOD, 42D
7 7
Compound 4 20 PO, QD, 42D
Compound 8 300 PO, QOD, 42D
8 7
Compound 10 20 PO, QD, 42D
In this ic study, seven mice were recruited in each group and animals received the
first dose at least 38 days post AAV-HBV ion. The tested combinations included
Compound 8 plus Compound 4, nd 8 plus Compound 10, and Compound 1 plus
Compound 10. All compounds were formulated as an inclusion complex with 2% Klucel LF,
0.1% Polysorbate 80, and 0.1% Parabens in water, and an equivalent volume of placebo
containing 2% Klucel LF, 0.1% Polysorbate 80, and 0.1% Parabens was used in the vehicle
group. Specifically, for the combination of Compound 8 plus Compound 4, 30mg/mL of
Compound 8 and 2mg/mL of Compound 4 were formulated. The group Compound 8 were
orally dosed at 300mg/kg QOD, while the group nd 4 were orally dosed at 20mg/kg
QD. And then the ponding Combo group received 30mg/kg of Compound 8 QOD plus
20mg/kg Compound 4 QD. For the combination of Compound 8 plus Compound 10,
30mg/mL of Compound 8 and 2mg/mL of Compound 10 were formulated. The group
Compound 8 were orally dosed at 300mg/kg QOD, while the group Compound 10 were orally
dosed at 20mg/kg QD. And then the corresponding Combo group received 300mg/kg of
Compound 8 QOD plus 20mg/kg Compound 10 QD. For the ation of Compound 1
plus Compound 10, 10mg/mL of Compound 1 and 2mg/mL of nd 10 were formulated.
The group Compound 1 was orally dosed at 100mg/kg QOD, while the group Compound 10
were orally dosed at 20mg/kg QD. And then the corresponding Combo group received
100mg/kg of nd 1 QOD plus 20mg/kg Compound 10 QD. After the first dose, mice
were submandibularly bled (75 μL blood/mouse) twice per week for serum collection until the
end of the studies. The collected blood were left at 37°C for at least 30 minutes to coagulate and
then centrifuged at 13,200 × g, 4°C for 3 minutes to obtain mouse serum. These serum samples
were subjected to analysis of HBV biomarkers.
The results in Figure 8 showed that TLR7 agonist Compound 8 alone reduced HBV DNA
and HBsAg by about 2-log and 1.5-log respectively at the end of the treatment, while the
combination of Compound 8 plus capsid inhibitor Compound 4 r d HBsAg to the
level below the LLQ. During the 6-week eatment period, the combination group
demonstrated sustainable HBsAg reduction, l HBV DNA rebound, and high levels of
anti-HBs which was not seen in vehicle and single treatment , as shown in Figure 11.
Such benefits of the combination treatment were also consistently ed in the combination
groups of Compound 8 plus Compound 10, and Compound 1 plus Compound 10, as shown
in Figures 9, 10, and 11.
In summary, the results above have proven for the first time that the combination of a
TLR7 t plus an HBV Capsid inhibitor is an effective therapy to greatly reduce or even
eliminate HBV DNA and HBsAg. After the combination therapy, the viral suppression has been
shown to last for as long as 6 weeks without treatment. In most chronically HBV-infected
patients, the current available therapies can rarely achieve HBsAg seroconversion due to the fact
that most of these therapies are unable to elicit anti-HBs (antibody against HBsAg). In our
combination studies, it is striking to find that anti-HBs has become detectable during the 6-week
off-treatment period, and this was most t in the mice taking the combination therapies as
shown in Figure 7 and 11. Therefore, the combination therapy of a TLR7 agonist plus an HBV
Capsid inhibitor offers another key benefit to promote the development of anti-HBs. As
sustained HBsAg loss and/or anti-HBs seroconversion is an ideal treatment nt for chronic
hepatitis B, our combination treatment represents a novel way to achieve clinical cure of chronic
HBV infection.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the ion. Unless ically stated otherwise,
reference to such external documents is not to be construed as an admission that such documents,
or such sources of information, in any jurisdiction, are prior art, or form part of the common
general knowledge in the art.
Claims (5)
1. A pharmaceutical composition comprising a TLR7 agonist and an HBV capsid assembly tor, in a pharmaceutically acceptable carrier, wherein the TLR7 agonist is selected from 5 [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl ]propyl] acetate having the structure 5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H- 10 thiazolo[4,5-d]pyrimidine-2,7-dione having the structure and wherein the HBV capsid assembly inhibitor is ed from 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4- 15 dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- dimethyl-propanoic acid having the structure 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4- dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- dimethyl-propanoic acid having the structure 5 ; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 2. The pharmaceutical composition according to claim 1, wherein the composition consists of 10 [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl ]propyl] e having the structure 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4- dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- 15 yl-propanoic acid having the structure in a pharmaceutically acceptable carrier. 3. The pharmaceutical composition according to claim 1, n the composition consists of 5 [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl ]propyl] e having the structure 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4- dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- 10 dimethyl-propanoic acid having the structure in a pharmaceutically acceptable carrier. 4. The pharmaceutical composition according to claim 1, wherein the composition consists of 5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H- thiazolo[4,5-d]pyrimidine-2,7-dione having the structure 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4- 5 opyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- dimethyl-propanoic acid having the structure in a pharmaceutically acceptable r. 5. The pharmaceutical composition according to claim 1, wherein the composition 10 consists of 5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H- thiazolo[4,5-d]pyrimidine-2,7-dione having the structure 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4- 15 dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- dimethyl-propanoic acid having the structure in a pharmaceutically acceptable carrier. 6. The pharmaceutical ition according to any one of claims 1 to 5, wherein the composition additionally comprises one or more other antiviral agents. 5 7. The pharmaceutical composition according to claim 6, wherein said other antiviral agents are selected from lamivudine, ir, tenofovir, telbivudine and entecavir. 8. A kit comprising a container comprising a TLR7 agonist and an HBV capsid assembly inhibitor, wherein the TLR7 t is selected from [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy- 10 tetrahydrofuranyl]propyl] acetate having the structure ; or 5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H- thiazolo[4,5-d]pyrimidine-2,7-dione having the structure or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; and n the HBV capsid assembly inhibitor is selected from 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4- dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- 5 dimethyl-propanoic acid having the structure ; or 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4- dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- dimethyl-propanoic acid having the structure 10 ; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 9. The kit according to claim 8, wherein the TLR7 t and the HBV capsid ly inhibitor used in the container are: [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy- 15 tetrahydrofuranyl]propyl] acetate and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)- 5-ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo [1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl ]propyl] acetate and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoro- 5 2-methyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo [1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; 5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H- thiazolo[4,5-d]pyrimidine-2,7-dione and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)- 5-ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8a- 10 tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; 5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H- thiazolo[4,5-d]pyrimidine-2,7-dione and 3-[(8aS)[[(4S)ethoxycarbonyl(3- fluoromethyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo- 15 5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; in a pharmaceutically able carrier. 10. The kit according to claim 9, further comprising a sterile diluent. 11. The kit according to any one of claims 8 to 10, further comprising a package insert comprising printed instructions directing the use of a combined treatment of a TLR7 agonist and 20 an HBV capsid assembly inhibitor as a method for treatment or laxis of tis B virus infection. 12. Use of a combination of a TLR7 agonist and a HBV capsid assembly tor, selected from the group consisting of: [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy- 25 tetrahydrofuranyl]propyl] acetate and S)[[(4R)(2-chlorofluoro-phenyl)- 5-ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo [1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; [(1S)[(2S,4R,5R)(5-aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxytetrahydrofuranyl ]propyl] acetate and S)[[(4S)ethoxycarbonyl(3-fluoro- yl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo [1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; 5 5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H- thiazolo[4,5-d]pyrimidine-2,7-dione and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)- 5-ethoxycarbonylthiazolyl-1,4-dihydropyrimidinyl]methyl]oxo-5,6,8,8atetrahydro-1H-imidazo [1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; 10 5-amino[(2R,3R,5S)hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H- thiazolo[4,5-d]pyrimidine-2,7-dione and S)[[(4S)ethoxycarbonyl(3- fluoromethyl-phenyl)thiazolyl-1,4-dihydropyrimidinyl]methyl]oxo- 5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2-dimethyl-propanoic acid; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof, 15 in the manufacture of one or more medicament for the treatment or prophylaxis of hepatitis B virus infection. 13. Use according to claim 12, wherein the combination is [(1S)[(2S,4R,5R)(5- aminooxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-tetrahydrofuranyl]propyl] acetate having the structure and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4- dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- dimethyl-propanoic acid having the structure or a ceutically acceptable salt, enantiomer or diastereomer thereof. 14. Use according to claim 12, wherein the combination is [(1S)[(2S,4R,5R)(5-
2-oxo-thiazolo[4,5-d]pyrimidinyl)hydroxy-tetrahydrofuranyl]propyl] 5 acetate having the structure and
3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,
4- dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,
5-a]pyrazinyl]-2,2- dimethyl-propanoic acid; 10 ; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 15. Use according to claim 12, wherein the combination is 5-amino[(2R,3R,5S) hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H-thiazolo[4,5-d]pyrimidine-2,7-dione having the structure 5 and 3-[(8aS)[[(4R)(2-chlorofluoro-phenyl)ethoxycarbonylthiazolyl-1,4- dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- dimethyl-propanoic acid; or a pharmaceutically acceptable salt, omer or diastereomer thereof. 10 16. Use according to claim 12, wherein the combination is 5-amino[(2R,3R,5S) hydroxy[(1S)hydroxypropyl]tetrahydrofuranyl]-6H-thiazolo[4,5-d]pyrimidine-2,7-dione having the structure and 3-[(8aS)[[(4S)ethoxycarbonyl(3-fluoromethyl-phenyl)thiazolyl-1,4- 15 dihydropyrimidinyl]methyl]oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazinyl]-2,2- yl-propanoic acid having the structure or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. 17. Use according to any one of claims 12 to 16, wherein the TLR7 agonist and the HBV capsid assembly inhibitor are formulated for co-administration in the same formulation or 5 different formulations. 18. Use according to any one of claims 12 to 17, n the TLR7 agonist and the HBV capsid assembly inhibitor are formulated for administration to a subject by the same route or different . 19. Use ing to any one of claims 12 to 18, wherein the TLR7 agonist and the HBV 10 capsid assembly inhibitor are formulated for administration to a subject by parenteral or oral administration. 20. Use according to any one of claims 12 to 19, wherein the TLR7 agonist and the HBV capsid assembly tor are formulated for simultaneous or sequential administration. 21. A pharmaceutical composition according to any one of claims 1 to 7, substantially as 15 herein described with nce to any example thereof. 22. A kit according to any one of claims 8 to 11, substantially as herein bed with reference to any example thereof. 23. Use according to any one of claims 12 to 20, substantially as herein described with reference to any example thereof. W0
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015074269 | 2015-03-16 | ||
CNPCT/CN2015/074269 | 2015-03-16 | ||
CNPCT/CN2015/074854 | 2015-03-23 | ||
CN2015074854 | 2015-03-23 | ||
CNPCT/CN2015/084480 | 2015-07-20 | ||
CN2015084480 | 2015-07-20 | ||
CN2016074012 | 2016-02-18 | ||
CNPCT/CN2016/074012 | 2016-02-18 | ||
PCT/EP2016/055484 WO2016146598A1 (en) | 2015-03-16 | 2016-03-15 | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ733805A NZ733805A (en) | 2021-04-30 |
NZ733805B2 true NZ733805B2 (en) | 2021-08-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7195360B2 (en) | Combination treatment with TLR7 agonists and HBV capsid assembly inhibitors | |
WO2017211791A1 (en) | Combination therapy of an hbsag inhibitor and a tlr7 agonist | |
JP7101663B2 (en) | Combination therapy of TLR7 agonist and HBV capsid assembly inhibitor | |
WO2017108630A1 (en) | Combination therapy of an hbsag inhibitor and an hbv capsid assembly inhibitor | |
NZ733805B2 (en) | Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor | |
BR112017019758B1 (en) | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | |
BR122021002683B1 (en) | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | |
JP2022533462A (en) | Oxalamide-substituted tricyclic inhibitors of hepatitis B virus |